furosemide and Blood Pressure, High studies

Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.

Research Excerpts

Excerpt	Relevance	Reference
"5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks."	9.19	Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014)
" We wanted to test the hypotheses that amiloride and spironolactone induced potassium retention reduces ambulatory blood pressure (ABP) and central blood pressure (CBP) during baseline conditions and after furosemide and that the tubular transport via the epithelial sodium channels (ENaCs) and aquaporin-2 (AQP2) water channels was increased by furosemide in arterial hypertension."	9.17	Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial. ( Jensen, JM; Larsen, T; Lauridsen, TG; Matthesen, SK; Pedersen, EB; Vase, H, 2013)
"Furosemide is the diuretic of choice for the treatment of hypertension in chronic kidney disease but the adaptative changes in the distal nephron may decrease its efficacy."	9.16	A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2012)
"The aim of this study was to evaluate the effects of both the prolonged-release (PR) formulation of torasemide (torasemide-PR) and furosemide on myocardial fibrosis in hypertensive patients with chronic HF."	9.15	Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. ( , 2011)
"Furosemide, either alone or in combination with captopril, is capable to prevent myocardial calcification, cardiac hypertrophy and hypertension, maintaining blood Ca(2+) and phosphate levels by slowing CRF."	9.14	Myocardial calcification and hypertension following chronic renal failure and ameliorative effects of furosemide and captopril. ( Kang, HS; Kim, JS; Kim, SJ; Kim, SZ; Lee, YU; Rahman, M, 2010)
"We compared the efficacy of long-acting furosemide (60 mg/day) and hydrochlorothiazide (25 mg/day) in a double-blind, randomized crossover trial in seven patients with severe renal failure and hypertension (seven men, 54+/-10 years old)."	9.11	A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2005)
"This investigation was undertaken to estimate whether a brief postpartum course of furosemide for patients with preeclampsia benefits recovery and shortens hospitalization by enhancing diuresis, lessening severe hypertension, and reducing the need for antihypertensive therapy."	9.11	Postpartum preeclampsia management with furosemide: a randomized clinical trial. ( Ascarelli, MH; Cushman, J; Johnson, V; Martin, JN; May, WL; McCreary, H, 2005)
"To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)."	9.08	Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995)
"The present study was performed to clarify changes in plasma levels of 19-hydroxyandrostenedione (19-OH-AD), an amplifier of aldosterone and a possible hypertensinogenic steroid, during several tests for the renin-angiotensin system in 20 patients with aldosterone-producing adenoma (APA) and to determine whether 19-OH-AD participates in the etiology of the hypertension in this disorder."	9.07	Low plasma 19-hydroxyandrostenedione levels in patients with aldosterone-producing adenoma. ( Miura, K; Miyazaki, S; Morita, H; Mune, T; Yamakita, N; Yasuda, K, 1993)
"In this study, the tolerability and safety of ramipril, as monotherapy and in combination with a low dose of furosemide, were assessed in patients with mild-to-moderate hypertension in general practice."	9.07	Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice. ( Carré, A; Elmalem, J; Thiéry, P; Vasmant, D, 1991)
"The open, long-term antihypertensive, hemodynamic and metabolic effects of betaxolol in combination with furosemide and minoxidil were investigated on 30 male patients with moderate to severe essential hypertension."	9.07	Cardiac changes from beta-blocker, diuretic and minoxidil combination in hypertension. ( Berlin, L; Chrysant, C; Chrysant, SG; Sadeghi, M, 1991)
"The antihypertensive effect and tolerability of enalaprilat, an intravenously administered angiotensin converting enzyme inhibitor, was studied in 65 patients with moderate or severe hypertension."	9.06	Effect of intravenous enalaprilat in moderate and severe systemic hypertension. ( Ayers, C; Davidson, R; DiPette, D; Fisher, M; Guthrie, G; Rucinska, E; Rutledge, J; Schwartz, S, 1988)
"Forty-four patients with mild to moderate essential hypertension were entered in an open study to compare the efficacy and tolerability of the two diuretic combinations, frusemide (40 mg) plus amiloride (5 mg) and hydrochlorothiazide (50 mg) plus amiloride (5 mg), as first-line treatment."	9.06	An open study to compare the efficacy and tolerability of two diuretic combinations, frusemide plus amiloride and hydrochlorothiazide plus amiloride, in patients with mild to moderate essential hypertension. ( Allman, S; Backhouse, CI; Crawford, RJ; Platt, J, 1988)
"Penbutolol is a new, potent and long-acting non-cardioselective beta-adrenergic blocker which has been evaluated in a 6-month open study of patients with moderate essential or renal hypertension."	9.05	Penbutolol in hypertension, alone and in combination with furosemide. A long-term multicentre study. ( Lawrence, J; Mertens, H; Rössner, M; Vander Elst, E, 1983)
"Forty-one patients completed a randomized, double-blind, between-group comparison of a combination of penbutolol and frusemide, with penbutolol alone, and frusemide alone in the management of mild to moderate essential hypertension."	9.05	A comparison of a combination of penbutolol and frusemide with the two compounds individually in the treatment of hypertension. ( Chadha, DR; Houtzagers, JJ, 1983)
"Forty patients completed a double-blind parallel group study comparing furosemide (FUR) and hydrochlorothiazide (HCT) when added to a stable dose of beta blocker in the treatment of mild to moderate hypertension."	9.05	Controlled comparison of the effects of furosemide and hydrochlorothiazide added to propranolol in the treatment of hypertension. ( Dombey, SL; Lawrence, J; Vander Elst, E; Vlassak, W, 1981)
"Minoxidil has been administered to 16 patients with severe hypertension and renal failure."	9.04	Minoxidil in severe hypertension. ( Mäkelä, M; Oka, M, 1978)
"Effect of long-term administration of propranolol was studied in 90 unselected patients with essential hypertension."	9.04	[Treatment of essential hypertension with propranolol (author's transl)]. ( Braun, B; Klaus, D; Klumpp, F; Lemke, R; Zehner, J, 1976)
" Group A: In 14 patients with essential hypertension on chlorthalidone treatment, an additional daily dose of 640 mg propranolol for two months led to a significant reduction of the MAP (from 124 to 105 mm Hg) and PRA (from 5."	9.04	Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension. ( Boer, P; Geyskes, GG; Leenen, FH; Mees, EJ; Vos, J, 1975)
"Activity of the circulating renin-angiotensin-aldosterone system (RAAS) has not been comprehensively characterized in cats with systemic hypertension (SH) or cardiomyopathy (CM), and the effects of furosemide or amlodipine treatment on the RAAS have not been fully evaluated in cats."	8.12	Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. ( Domenig, O; Guillot, E; Mochel, JP; Ward, JL; Ware, WA; Yuan, L, 2022)
"Furosemide is a loop diuretic drug frequently indicated in hypertension and fluid overload conditions such as congestive heart failure and hepatic cirrhosis."	7.85	Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions. ( Kodati, D; Yellu, N, 2017)
"Kidney-specific induction of heme oxygenase-1 (HO-1) attenuates the development of angiotensin II (Ang II) -dependent hypertension, but the relative contribution of vascular versus tubular induction of HO-1 is unknown."	7.78	Expression of heme oxygenase-1 in thick ascending loop of henle attenuates angiotensin II-dependent hypertension. ( Abraham, NG; Csongradi, E; Drummond, HA; Gousette, MU; Stec, DE; Storm, MV, 2012)
"In order to determine how both diuretics affect water metabolism, we here compare the effects of a rechallenge with either amiloride-hydrochlorothiazide fixed association (AmHTZ; amiloride chlorhydrate 5 mg+hydrochlorothiazide 50 mg; Moduretic) or furosemide (F; 40 mg; Lasix) on water excretion in a 79 year old woman who was previously admitted for severe symptomatic hyponatremia secondary to a 5 days course of AmHTZ for systolic hypertension."	7.75	Safety of furosemide administration in an elderly woman recovered from thiazide-induced hyponatremia. ( Cogan, E; Fadel, S; Karmali, R, 2009)
"The relationship between renin responsiveness to furosemide and the antihypertensive effect of captopril in patients with normal-renin essential hypertension were studied in 23 patients including nine men (mean age, 41 years) and 14 women (mean age, 40 years)."	7.68	Correlation between renin responsiveness to furosemide and antihypertensive effect of captopril in patients with normal-renin essential hypertension. ( Chen, YM; Chu, TS; Fang, CC; Hsieh, BS, 1993)
"Patients with essential hypertension (n = 2969) who had not been taking any blood pressure medication for longer than 1 week were classified as furosemide-sensitive (FS) if their diastolic BP after furosemide fell > or = 10% and furosemide-resistant (FR) if it fell less than that."	7.68	Increased prevalence of cardiovascular complications in women with furosemide resistant essential hypertension. ( Anderson, GH; Blakeman, N; Newman-Palmer, N; Streeten, DH, 1993)
" In 10 patients with essential hypertension, we investigated the influence of betaxolol, a selective beta 1-adrenergic blocking agent, on renal function and on plasma levels of ANP during exercise, volume depletion and volume expansion."	7.68	Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. ( Grabensee, B; Heering, P; Hollenbeck, M; Kutkuhn, B; Plum, J, 1991)
"Plasma levels of atrial natriuretic peptide (ANP) were measured in patients with normal renin essential hypertension (n = 12), low renin essential hypertension (n = 11) and primary aldosteronism due to aldosterone producing adenoma (APA, n = 8) and idiopathic hyperaldosteronism (IHA, n = 3) after overnight rest in the supine position and after 4 h upright posture and furosemide administration."	7.68	Dissociation of plasma atrial natriuretic peptide responses to upright posture and furosemide administration in patients with normal-, low renin essential hypertension and primary aldosteronism. ( Fütö, L; Gláz, E; Gutkowska, J; Kiss, R; Rácz, K; Sergev, O; Varga, I, 1991)
"The arterial pressure, the pulse frequency, the concentration of arterial natriuretic peptide (ANP), the aldosterone++ concentration and the plasma renin activity were determined in patients with primary hypertension after administration of furosemide in conditions of active assuming of erect position."	7.68	[Effects of 4-hour erect posture and furosemide on the blood level of atrial natriuretic peptide in patients with primary arterial hypertension]. ( Chlebus, H; Chodakowska, J; Ignatowska-Switalska, H; Januszewicz, A; Januszewicz, W; Lapiński, M; Stepniakowski, K; Wocial, B, 1990)
"This study investigated the ability of two diuretics, amiloride and frusemide, to prevent the development of ACTH induced hypertension in conscious sheep."	7.68	Amiloride blocks the onset of ACTH-induced hypertension in the sheep. ( Coghlan, JP; Reid, AF; Scoggins, BA; Whitworth, JA, 1990)
"Dynamic I-123 Hippuran renal studies to measure furosemide response (FR) were performed in three groups of patients: 1) 57 patients with renovascular hypertension due to a poststenotic, ischemic kidney; 2) 23 patients with essential hypertension; and 3) 50 nonhypertensive patients with healthy kidneys (control group)."	7.68	Diminished response to furosemide in I-123 Hippuran renal studies of renovascular hypertension caused by unilateral renal artery stenosis. ( Einspieler, R; Flueckiger, FM; Fueger, GF; Hausegger, K, 1990)
"Clinical, hemodynamic and neurohumoral data are available supporting the validity of a differentiated approach to administration of combined treatment with furosemide, digoxin and calcium antagonists nifedipine and verapamil in advanced-aged patients with hypertension complicated by circulatory disorders."	7.68	[Evaluation of the effectiveness of calcium antagonists combined with digoxin and furosemide in hypertension complicated by circulatory insufficiency in elderly patients]. ( Orynchak, MA, 1990)
"The article reports the efficacy and tolerability of a new slow-release formulation of furosemide (Lasix Retard) given to an elderly (mean: 72 years, range 48-92) population (n = 115, 77 females) suffering from hypertension or heart failure."	7.68	[Furosemide capsules in the treatment of hypertension or heart failure in the elderly in general practice]. ( Terland, O, 1990)
"We studied the possible interplay between plasma bradykinin (P-BK) and the renin-angiotensin axis in essential hypertension, the effect of catecholamine on P-BK by standing and norepinephrine (NE) infusion, and the possible role of bradykinin in the hypotensive mechanism of angiotensin I converting enzyme inhibitor (captopril) in renin-independent essential hypertension."	7.67	[The effect of alterations of the renin-angiotensin system and the sympathetic nervous system on plasma bradykinin concentration in patients with essential hypertension]. ( Takeda, Y, 1984)
"We examined the urinary excretion of prostaglandin (PG)E2 and PGF2 alpha before and 15 min after stimulation with the acutely vasodilating agent furosemide in 25 normotensive controls and 81 patients with essential hypertension (EH)."	7.67	Prostaglandin excretion after furosemide in normal and low-renin essential hypertension. ( Scherer, B; Weber, PC; Witzgall, H, 1984)
"Studies were carried out in 15 patients with renal insufficiency and hypertension to compare the long-term effects of methyldopa and propranolol on renal hemodynamics."	7.67	Comparison of long-term renal hemodynamic effects of methyldopa and propranolol in patients with hypertension and renal insufficiency. ( Alterman, L; Bank, DE; Bank, N; Lowenstein, I; Zelen, R, 1984)
"In order to identify the hemodynamics of borderline essential hypertension, radionuclide angiography was performed before and after bolus injection of furosemide (40 mg i."	7.67	Hemodynamics in borderline hypertension: acute effect of furosemide. ( Barletta, GA; Bisi, G; Fabbri, G; Franchi, F; Malfanti, PL; Pedenovi, P; Scardi, A, 1984)
"Our previous study demonstrated increased sodium (Na+) influx into ouabain-treated erythrocytes in diabetic patients with hypertension."	7.67	Increased furosemide-sensitive sodium influx into erythrocytes in non-insulin-dependent diabetes mellitus associated with hypertension. ( Chimori, K; Dodo, S; Goi, R; Goto, S; Hayashi, H; Izai, M; Miura, K; Miyazaki, S; Yasuda, K, 1989)
"Thirty patients with moderate to severe, uncontrolled hypertension were treated with a captopril/frusemide combination."	7.67	Low dose, twice daily captopril and frusemide: a safe, effective and flexible third line treatment regimen for hypertension. ( Corrie, J; Flapan, AD; Lindsay, BA; Padfield, PL; Rademaker, M, 1989)
"Fifty two patients with severe hypertension were treated with parentral chlorpromazine and frusemide."	7.67	Chlorpromazine and frusemide in the acute management of severe hypertension. ( Chikanza, IC; Okwanga, PN, 1989)
"Nifedipine, in a slow release preparation, was given at a mean daily dosage of 47 +/- 4 mg to 12 patients with severe hypertension in whom arterial pressure was not satisfactorily controlled (mean blood pressure, 172 +/- 6/111 +/- 4 mmHg) by the association of a converting enzyme inhibitor and a diuretic."	7.67	Effect of nifedipine in hypertension not controlled by converting enzyme inhibitor and diuretic. ( Mimran, A; Ribstein, J, 1986)
"The purpose of this study was to define the effect of the angiotensin-converting enzyme inhibitor, enalapril maleate, on blood pressure, renal function, protein excretion, and potassium homeostasis in patients with hypertension associated with moderate to severe renal dysfunction."	7.67	Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. ( Bauer, JH; Reams, GP, 1986)
"Changes in plasma active and inactive renin and angiotensin II in response to tilt and intravenous frusemide were assessed in ten patients with essential hypertension, before treatment and again during chronic therapy with the alpha 1-adrenoceptor antagonist prazosin."	7.67	The effect of chronic prazosin therapy on the response of the renin-angiotensin system in patients with essential hypertension. ( Fulton, JD; Leckie, BJ; Malatino, LS; McAreavey, D; Morton, JJ; Murray, GD; Robertson, JI; Webb, DJ, 1987)
"The effect of captopril on renal plasma flow (RPF), glomerular filtration rate (GFR), plasma concentrations of renin, angiotensin II (Ang II), aldosterone (Aldo) and arginine vasopressin (AVP), serum osmolality (Sosm), free water clearance (CLH2O), fractional urinary excretion of electrolytes and blood pressure (BP), was examined in 10 patients with moderate essential hypertension."	7.67	Effect of captopril on renal haemodynamics and the renin-angiotensin-aldosterone and osmoregulatory systems in essential hypertension. ( Danielsen, H; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1986)
"Plasma concentrations of arginine vasopressin (AVP), angiotensin II (AII), aldosterone (Aldo), urinary output (V), osmolar clearance (Cosm), free water clearance (CH2O), fractional excretions of sodium (FENa) and potassium (FEK), urinary sodium excretion rate (U-Na) and serum potassium (S-K) were determined in 9 patients with essential hypertension (group I) and 13 normotensive healthy control subjects (group II) before and three times during the first 4 hours after an intravenous injection of 40 mg of furosemide."	7.67	Abnormal vasopressin and aldosterone response to furosemide in essential hypertension. ( Danielsen, H; Madsen, M; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1986)
" After favourable results obtained in a preliminary study using a combination of parenteral chlorpromazine and frusemide, a 5-year prospective study was conducted using this treatment to produce rapid reduction in blood pressure in patients with acute onset severe hypertension (blood pressure greater than 225/130 mmHg)."	7.67	Parenteral chlorpromazine and frusemide: safe and effective treatment for hypertensive emergencies. ( Lawson, AA; Nimmo, GR, 1986)
"10 patients with severe refractory hypertension were treated with captopril and frusemide."	7.66	Captopril and frusemide in severe drug-resistant hypertension. ( Ledingham, JG; Rajagopalan, B; White, NJ; Yahaya, H, 1980)
"Twenty patients with severe hypertension and chronic renal failure were given Captopril during a one year period."	7.66	[Long-term treatment with captopril in arterial hypertension complicated by renal failure]. ( Ader, JL; Bories, P; Durand, D; Emal, V; Girolami, JP; Suc, JM, 1982)
"14 patients with refractory hypertension did not respond either to captopril, an angiotensin II converting enzyme inhibitor, combined with a diuretic, a beta-blocker and hydralazine or minoxidil, a potent vasodilator, but they did respond to the combination of captopril, minoxidil, furosemide and a beta-blocker."	7.66	Captopril combined with minoxidil, beta-blocker and furosemide in the treatment of refractory hypertension. ( Rawat, R; Seedat, YK, 1983)
"Five patients presenting with severe hypertension who failed to exhibit diastolic blood pressures less than 120 mm Hg following the oral administration of propranolol (60--80 mg) and furosemide (40 mg) received minoxidil (20 mg, p."	7.66	Rapid reduction of severe hypertension with minoxidil. ( Alpert, MA; Bauer, JH, 1980)
"The humoral and hemodynamic effects of converting enzyme inhibition captopril are presented in two patients with primary hyperaldosteronism (PHA)."	7.66	Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism. ( Demers, LM; Harrison, TS; Hayes, AH; Luderer, JR, 1982)
"Alterations in the concentration of plasma dehydroepiandrosterone sulfate (DHEA-S) and cortisol in patients with essential hypertension (EH) were investigated."	7.66	A study on dehydroepiandrosterone sulfate in patients with essential hypertension. ( Hatano, M; Honda, M; Tsuchiya, M, 1982)
"The response of plasma renin activity (PRA), plasma aldosterone, 18-hydroxycorticosterone (18-OH-B), 18-hydroxydeoxycorticosterone (18-OH-DOC) and corticosterone to furosemide were compared in 20 normal control subjects, 16 patients with normal-renin essential hypertension (NREH) and 12 patients with low-renin essential hypertension (LREH)."	7.66	Rapid increase of mineralocorticoids after furosemide in low-renin essential hypertension: evidence for 18-hydroxycorticosterone to be a better marker than aldosterone. ( Thayil, G; Weber, PC; Witzgall, H, 1982)
"The 24-h urinary excretion of prostaglandins (PG) E2 and F2 alpha, which reflects the renal synthesis of these substances, was measured by radioimmunoassay in 10 patients with essential hypertension before and after treatment with propranolol."	7.66	Effect of propranolol treatment on the urinary excretion of prostaglandins E2 and F2 alpha in patients with essential hypertension. ( Bernheim, J; Rathaus, M, 1982)
"26 patients with severe hypertension (10 essential, 9 renal parenchymatous, 7 renovascular) and a mean age of 42 years were treated with the new oral converting enzyme inhibitor captopril (SQ 14225)."	7.66	[Captopril in treatment-resistant hypertension (author's transl)]. ( Lüscher, T; Siegenthaler, W; Studer, A; Vetter, W, 1980)
"To investigate the pathogenic role of the sympathetic nervous system and the renin-angiotensin system in essential hypertension, we evaluated plasma catecholamine and PRA levels after glucagon stimulation and during one hour in upright posture after i."	7.66	[Response of plasma catecholamine and PRA to i.v. injection of glucagon in upright posture after furosemide injection in essential hypertension (author's transl)]. ( Uda, M, 1981)
"In an open multi-centre study, 51 patients with mild to moderate hypertension were treated with either a single dose of 40 mg penbutolol per day for 8 weeks or changed over at 4 weeks due to inadequate response with penbutolol alone to a single dose (1 tablet) of a fixed combination of 40 mg penbutolol and 20 mg furosemide per day for a further 4 weeks."	7.66	Efficacy of penbutolol and a fixed combination of penbutolol with furosemide in the treatment of hypertension. ( Graml, W; Haeringer, E; Rangoonwala, B; Roessner, M, 1982)
"Male and female, Sprague-Dawley rats, with and without arteriosclerosis, were subjected to chronic treatment with furosemide for 4 weeks."	7.66	Furosemide-induced hyperuricemia, hyperglycemia, hypertension and arterial lesions in nonarteriosclerotic and arteriosclerotic rats. ( Wexler, BC, 1981)
"Eighty-seven patients with intractable hypertension received minoxidil for a mean duration of 27 months (range three months to five years)."	7.66	Minoxidil in the management of intractable hypertension. ( Fife, R; Henderson, I; Isles, C; Kennedy, AC; Mackay, A, 1981)
"8 years) with a therapy-resistant hypertension were for 10 days treated with injections of diazoxide and furosemide (hypertonalum and furesis)."	7.66	[Changes in plasma volume and electrolytes after treatment of therapy-resistant hypertension with diazoxide and furosemide]. ( Cebulla, P; Herrmann, RM; Kiesewetter, R; Stoll, W, 1981)
" injection of furosemide in 10 normal subjects and in 10 patients with essential hypertension."	7.66	Effect of furosemide on renal prostaglandins E2 and F2 alpha in normal subjects and in patients with essential hypertension. ( Bauminger, S; Bernheim, J; Rathaus, M, 1980)
"Two groups of 10 patients with systemic arterial hypertension were studied by respiratory function tests before and after acute administration of diazoxide or furosemide."	7.66	Systemic arterial hypertension and small airways function: acute effects of diazoxide and furosemide. ( Accatino, G; Bucca, C; Galeasso, B; Pecchio, O; Ratti, C; Rolla, G, 1980)
"Plasma concentrations of angiotensin II (AII), aldosterone, 18-hydroxycorticosterone and cortisol were measured in seven patients with benign essential hypertension and in seven age-matched control subjects before, and at frequent intervals for 2 h after the intravenous injection of frusemide (40 mg)."	7.66	Increased 18-hydroxycorticosterone responses to frusemide in essential hypertension. ( Fraser, R; Mason, PA; Semple, PF, 1980)
"Pericardial effusions are occasionally observed in patients treated with the new oral vasodilator, minoxidil."	7.66	Pericardial effusion associated with minoxidil therapy. ( Chatterjee, K; Houston, MC; McChesney, JA, 1981)
"In essential hypertension mean basal (supine) and stimulated plasma renin activity (2 h upright posture + 40 mg furosemide intraveneously) decreased progressively with age."	7.66	Age- and sex-related differences in plasma aldosterone in essential hypertension. Relationship to plasma renin activity. ( Alasso, I; Glänzer, K; Vetter, H; Vetter, W, 1979)
"Plasma concentrations of angiotensin II (AII) were studied in 36 patients with primary (essential) hypertension and 15 normotensive control subjects during basal (1 h supine rest), upright and frusemide-stimulated (80 mg orally) conditions."	7.66	Angiotensin II in primary hypertension, relationship to plasma renin activity, aldosterone and urinary electrolytes. ( Karlberg, BE; Tolagen, K, 1979)
"The effect of furosemide on urinary kallikrein excretion was studied in 10 patients with essential hypertension and 9 normal volunteer subjects."	7.66	Effect of furosemide on urinary kallikrein excretion in patients with essential hypertension. ( Abe, K; Chiba, S; Irokawa, N; Ito, T; Kusaka, T; Miyazaki, S; Ritz, K; Saito, K; Sakurai, Y; Seino, M; Yasujima, M; Yoshinaga, K, 1978)
"Studies were undertaken to determine if the dissociation of aldosterone and plasma renin activity in low-renin essential hypertension is due to altered adrenal responsiveness to angiotensin II."	7.66	Increased adrenal sensitivity to angiotensin II in low-renin essential hypertension. ( Brown, RD; Wisgerhof, M, 1978)
"To study whether the renin-angiotensin system is related to hyperuricemia in hypertension, the serum concentration of uric acid was determined in 96 patients with various types of hypertension and various degrees of plasma renin activity (PRA)."	7.66	Serum uric acid and the renin-angiotensin system in hypertension. ( Kato, E; Kondo, K; Nakamura, R; Oguro, T; Ozawa, Y; Saito, I; Saruta, T; Yamagami, K, 1978)
"The possibility has been explored of using a specific angiotensin ii antagonist, saralasin (P-113, 1-sar-8-ala-angiotensin ii) to recognize patients whose hypertension depends upon excessive angiotensin ii activity."	7.65	Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;. ( Anderson, GH; Dalakos, TG; Freiberg, JM; Streeten, DH, 1975)
" Propranolol and furosemide were administered concomitantly to control reflex tachycardia and fluid retention."	7.65	The outpatient treatment of refractory hypertension with minoxidil. ( Ball, JH; Kleiner, JP; Nelson, WP; Norton, JD, 1977)
"Urinary excretion of prostaglandin E was measured radioimmunologically in 19 healthy persons (15 men and 4 women) and in 16 patients (10 men and 6 women) with essential hypertension before and after the administration of furosemide."	7.65	Effect of furosemide on urinary excretion of prostaglandin E in normal volunteers and patients with essential hypertension. ( Abe, K; Chiba, S; Irokawa, N; Ito, T; Saito, T; Yasujima, M; Yoshinaga, K, 1977)
"Changes in arterial blood pressure, renal electrolyte excretion, and plasma renin activity in response to repeated doses of furosemide were measured in 12 patients with essential hypertension admitted to the medical service for electrolyte balance studies."	7.65	Furosemide and plasma renin activity in essential hypertension. ( Hutcheon, DE; Sandhu, R, 1976)
"Plasma aldosterone, plasma renin activity, sodium and potassium in the plasma and the urine were determinated under acute stimulation with saline-depletion (furosemide) and under acute suppression with saline infusion in 40 patients with primary hypertension stage I, 19 patients with primary hypertension stages II and III, and 11 patients with renal hypertension (chronic glomerulonephritis and chronic pyelonephritis)."	7.65	[Plasma aldosterone and plasma renin activity in patients with essential and renal hypertension under acute stimulation with saline depletion and acute suppression with saline infusion]. ( Klaus, D; Klumpp, F; Lemke, R; Zehner, J; Zöfel, P, 1975)
"Thirteen patients with severe hypertension were treated with combined minoxidil, propranolol, and furosemide (mean daily doses 33 mg, 475 mg, and 578 mg, respectively) for nine to twenty-five months (mean 13."	7.65	Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide. ( Bennet, CM; Blaufuss, A; Wilburn, RL, 1975)
"Twenty-six patients were selected for treatment with minoxidil on the basis of hypertension which could not be controlled either because of (1) drug failures and/or (2) side effects of drugs."	7.65	Minoxidil in severe hypertension: value when conventional drugs have failed. ( Dormois, JC; Nies, AS; Young, JL, 1975)
"The anti-hypertensive effect of spironolactone and thiabutazide was tested on 47 unselected patients with primary hypertension."	7.65	[Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)]. ( Braun, B; Klaus, D; Klump, F; Lemke, R; Zehner, J; Zöfel, P, 1975)
"Treatment with oral diazoxide for periods of 4 to 10 weeks in hospital allowed adequate control of hypertension with continuation of fetal growth in four patients with severe toxaemia."	7.65	Successful use of oral diazoxide in the treatment of severe toxaemia of pregnancy. ( Davis, D; Morgan, MY; Pohl, JE; Thurston, H, 1972)
" All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12."	6.68	The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995)
"Lacidipine was not very effective in controlling blood pressure and had an adverse effect on renal function."	6.68	Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency. ( Bailey, RR; Lynn, KL; Robson, RA; Shand, BI; Smith, AH, 1997)
"Ramipril 5 mg daily was effective in 55."	6.67	The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension. ( Carré, A; Vasmant, D; Zannad, F, 1992)
" It is concluded that a gradual fall in BP can be obtained after fractionated dosage of diazoxide (i."	6.66	Severe hypertension with cerebral symptoms treated with furosemide, fractionated diazoxide or dihydralazine. Danish Multicenter Study. ( Hilden, T; Krogsgaard, AR; McNair, A; Nielsen, PE, 1986)
"Treatment with labetalol alone or in combination with furosemide, as well as methyldopa plus furosemide, was associated with significant reductions in supine and standing blood pressure levels."	6.65	Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial. ( Langford, H; Maloy, J; Maronde, RF; Michelson, EL; Poland, M; Wallin, JD; Wilson, D; Winer, N, 1983)
"Oxprenolol was the best tolerated drug, with only 5% of patients withdrawing due to side-effects compared to 13% on spironolacone and 29% on methyldopa."	6.64	Renin unresponsiveness and the effects of oxprenolol, methyldopa and spironolactone in pateints with essential hypertension. ( Beilin, LJ; Ledingham, JG; Thomas, GW; Yeates, KM, 1976)
"Primary aldosteronism (PA) is a well-known cause of secondary hypertension."	5.91	Simple standing test without furosemide is useful in the diagnosis of primary aldosteronism. ( Fushimi, Y; Iwamoto, H; Iwamoto, Y; Kaku, K; Kaneto, H; Katakura, Y; Kimura, T; Kusano, T; Mune, T; Nakanishi, S; Ohnishi, M; Sanada, J; Shimoda, M; Takenouchi, H; Tatsumi, F, 2023)
"Hypertension is a major risk factor for atherogenesis and heart hypertrophy, both of which are associated with specific morphological and functional changes of the myocardium."	5.43	Furosemide modifies heart hypertrophy and glycosaminoglycan myocardium content in a rat model of neurogenic hypertension. ( Karakiulakis, G; Kouvelas, D; Manthou, ME; Papakonstantinou, E; Pourzitaki, C; Tsaousi, G, 2016)
"Then furosemide treatment was stopped and the rat food was changed to 1% NaCl diet."	5.30	Effects of renal papillary-medullary lesion on the antihypertensive effect of furosemide and development of salt-sensitive hypertension in Dahl-S rats. ( Christensen, S; Haugan, K; Marcussen, N; Petersen, JS; Shalmi, M; Spannow, J, 1997)
"A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome."	5.28	Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome. ( Friedler, A; Mor, F; Shapira, Y; Weinberger, A; Wysenbeek, AJ, 1990)
" The purpose of the present study was to examine whether long-term therapy with ramipril (RA, and ACE inhibitor) would lower blood pressure more effectively and without adverse reactions in combination with the loop diuretics piretanide (PI) or furosemide (FU)."	5.28	Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats. ( Baldes, L; Becker, RH; Treudler, M, 1989)
" A booster dosage of 5 to 20 mg of minoxidil was given at four hours if the diastolic BP exceeded 100 mm Hg."	5.26	Rapid control of severe hypertension with minoxidil. ( Alpert, MA; Bauer, JH, 1982)
"Screening tests for primary aldosteronism were compared in 22 patients with this disorder and 140 hypertensive controls."	5.26	Simplified screening procedures for primary aldosteronism. Studies on the mechanism of the hyper-responsiveness to furosemide and standing. ( Anderson, GH; Streeten, DH, 1982)
"Low-renin hypertension was diagnosed by the presence of hypertension, hypokalaemic alkalosis, suppressed plasma renin activity and low plasma aldosterone."	5.26	Low-renin, low-aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child. ( Fiselier, TJ; Honour, JW; Monnens, LA; Otten, BJ; van Munster, PJ, 1982)
"The saralasin test was performed in 68 hypertensives."	5.26	[The saralasin test in the diagnosis of hypertension (author's transl)]. ( Bönner, G; Helber, A; Hummerich, W; Kaufmann, W; Meurer, KA; Wambach, G, 1979)
"To evaluate the effectiveness of furosemide in accelerating blood pressure recovery among women with severe preeclampsia."	5.20	Diuretics vs. placebo for postpartum blood pressure control in preeclampsia (DIUPRE): a randomized clinical trial. ( Amorim, M; Coutinho, I; Cursino, T; Katz, L, 2015)
"5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks."	5.19	Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014)
" We wanted to test the hypotheses that amiloride and spironolactone induced potassium retention reduces ambulatory blood pressure (ABP) and central blood pressure (CBP) during baseline conditions and after furosemide and that the tubular transport via the epithelial sodium channels (ENaCs) and aquaporin-2 (AQP2) water channels was increased by furosemide in arterial hypertension."	5.17	Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial. ( Jensen, JM; Larsen, T; Lauridsen, TG; Matthesen, SK; Pedersen, EB; Vase, H, 2013)
"Furosemide is the diuretic of choice for the treatment of hypertension in chronic kidney disease but the adaptative changes in the distal nephron may decrease its efficacy."	5.16	A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2012)
"The aim of this study was to evaluate the effects of both the prolonged-release (PR) formulation of torasemide (torasemide-PR) and furosemide on myocardial fibrosis in hypertensive patients with chronic HF."	5.15	Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. ( , 2011)
"Furosemide, either alone or in combination with captopril, is capable to prevent myocardial calcification, cardiac hypertrophy and hypertension, maintaining blood Ca(2+) and phosphate levels by slowing CRF."	5.14	Myocardial calcification and hypertension following chronic renal failure and ameliorative effects of furosemide and captopril. ( Kang, HS; Kim, JS; Kim, SJ; Kim, SZ; Lee, YU; Rahman, M, 2010)
"We compared the efficacy of long-acting furosemide (60 mg/day) and hydrochlorothiazide (25 mg/day) in a double-blind, randomized crossover trial in seven patients with severe renal failure and hypertension (seven men, 54+/-10 years old)."	5.11	A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. ( Berland, Y; Dussol, B; Morange, S; Moussi-Frances, J; Mundler, O; Somma-Delpero, C, 2005)
"This investigation was undertaken to estimate whether a brief postpartum course of furosemide for patients with preeclampsia benefits recovery and shortens hospitalization by enhancing diuresis, lessening severe hypertension, and reducing the need for antihypertensive therapy."	5.11	Postpartum preeclampsia management with furosemide: a randomized clinical trial. ( Ascarelli, MH; Cushman, J; Johnson, V; Martin, JN; May, WL; McCreary, H, 2005)
"The combination of losartan and low-dose diuretics effectively treated hypertension in elderly patients while minimizing the metabolic consequences of diuretic therapy."	5.09	Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker. ( Kohno, M; Masugata, H; Ohmori, K; Ohnishi, K; Takagi, Y; Wada, Y; Yukiiri, K, 2001)
"To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)."	5.08	Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995)
"To evaluate the metabolic effects of two anti-hypertensive agents with different actions, nifedipine 20 mg twice daily and furosemide 60 mg twice daily, 23 patients with untreated essential hypertension performed a double-blind, cross-over study in treatment periods of 5 months."	5.08	Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. ( Berne, C; Lind, L; Lithell, H; Pollare, T, 1995)
"The present study was performed to clarify changes in plasma levels of 19-hydroxyandrostenedione (19-OH-AD), an amplifier of aldosterone and a possible hypertensinogenic steroid, during several tests for the renin-angiotensin system in 20 patients with aldosterone-producing adenoma (APA) and to determine whether 19-OH-AD participates in the etiology of the hypertension in this disorder."	5.07	Low plasma 19-hydroxyandrostenedione levels in patients with aldosterone-producing adenoma. ( Miura, K; Miyazaki, S; Morita, H; Mune, T; Yamakita, N; Yasuda, K, 1993)
"In this study, the tolerability and safety of ramipril, as monotherapy and in combination with a low dose of furosemide, were assessed in patients with mild-to-moderate hypertension in general practice."	5.07	Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice. ( Carré, A; Elmalem, J; Thiéry, P; Vasmant, D, 1991)
"The open, long-term antihypertensive, hemodynamic and metabolic effects of betaxolol in combination with furosemide and minoxidil were investigated on 30 male patients with moderate to severe essential hypertension."	5.07	Cardiac changes from beta-blocker, diuretic and minoxidil combination in hypertension. ( Berlin, L; Chrysant, C; Chrysant, SG; Sadeghi, M, 1991)
"In the present study, circadian influences of furosemide on serum electrolytes, lipids and glucose were evaluated in ten hypertensive subjects."	5.07	Chronotherapeutic study of furosemide in hypertensive subjects: a preliminary report. ( Ebihara, A; Fujimura, A; Ohashi, K, 1991)
"The 770 subjects enrolled into the French multicenter trial of Triatec (ramipril) presented the usual characteristics of moderate hypertension."	5.06	[Efficacy of Triatec in monotherapy and in combination with Lasilix in a French multicenter study]. ( Guyot, D; Lemarié, JC, 1990)
"In a multicenter study in general practice, the tolerability and safety of ramipril alone and in combination with a low dose of furosemide were assessed in moderate hypertension."	5.06	[Tolerance to Triatec in monotherapy and in combination with Lasilix in a French multicenter study]. ( Elmalem, J, 1990)
"In order to assess whether blood pressure reduction with atenolol or enalapril is associated with changes in renal prostaglandin (PG) synthesis, we studied the effects of 10 weeks therapy in 20 subjects with mild or moderate hypertension."	5.06	Effects of atenolol and enalapril on blood pressure, plasma renin activity and urinary prostanoids. ( Wilson, TW, 1988)
"The antihypertensive effect and tolerability of enalaprilat, an intravenously administered angiotensin converting enzyme inhibitor, was studied in 65 patients with moderate or severe hypertension."	5.06	Effect of intravenous enalaprilat in moderate and severe systemic hypertension. ( Ayers, C; Davidson, R; DiPette, D; Fisher, M; Guthrie, G; Rucinska, E; Rutledge, J; Schwartz, S, 1988)
" The effects of exercise on coronary hemodynamics were determined in eight patients with mild essential uncomplicated hypertension, before and after treatment with furosemide (50 mg, to ensure activation of the renin-angiotensin system)."	5.06	Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. ( Ciulla, M; Magrini, F; Meazza, R; Reggiani, P; Roberts, N; Zanchetti, A, 1988)
"Forty-four patients with mild to moderate essential hypertension were entered in an open study to compare the efficacy and tolerability of the two diuretic combinations, frusemide (40 mg) plus amiloride (5 mg) and hydrochlorothiazide (50 mg) plus amiloride (5 mg), as first-line treatment."	5.06	An open study to compare the efficacy and tolerability of two diuretic combinations, frusemide plus amiloride and hydrochlorothiazide plus amiloride, in patients with mild to moderate essential hypertension. ( Allman, S; Backhouse, CI; Crawford, RJ; Platt, J, 1988)
"The pharmacodynamic effects of torasemide, a new potent loop diuretic, were compared with those of furosemide in a double blind controlled study in 18 hypertensive patients with oedema of various origins."	5.06	Torasemide, a new potent diuretic. Double-blind comparison with furosemide. ( Broekhuysen, J; Deger, F; Douchamps, J; Ducarne, H; Herchuelz, A, 1986)
" The incidence of severe hypertension was significantly lower when nifedipine (odds ratio, 0."	5.05	Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. ( Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020)
"Penbutolol is a new, potent and long-acting non-cardioselective beta-adrenergic blocker which has been evaluated in a 6-month open study of patients with moderate essential or renal hypertension."	5.05	Penbutolol in hypertension, alone and in combination with furosemide. A long-term multicentre study. ( Lawrence, J; Mertens, H; Rössner, M; Vander Elst, E, 1983)
"Forty-one patients completed a randomized, double-blind, between-group comparison of a combination of penbutolol and frusemide, with penbutolol alone, and frusemide alone in the management of mild to moderate essential hypertension."	5.05	A comparison of a combination of penbutolol and frusemide with the two compounds individually in the treatment of hypertension. ( Chadha, DR; Houtzagers, JJ, 1983)
"A single-blind trial was carried out in 36 people with mild to moderate hypertension to compare the efficacy and tolerance of long-term treatment with furosemide and chlorthalidone."	5.05	Long-acting and short-acting diuretics in the treatment of hypertension. ( Ansuini, R; Belogi, M; Campolucci, G; Pupita, F, 1983)
"The Authors have examined, by statistical analysis of the variance for a three-period cross-over design, the effects of fenquizone, furosemide and chlorthalidone on 24 in-patients affected by hypertension, edematous cardiac, renal and liver diseases."	5.05	[Clinical trial of the activity and therapeutic effectiveness of 3 drugs with diuretic and antihypertensive action]. ( Corinaldesi, G; Tiberi, F, 1981)
"Forty patients completed a double-blind parallel group study comparing furosemide (FUR) and hydrochlorothiazide (HCT) when added to a stable dose of beta blocker in the treatment of mild to moderate hypertension."	5.05	Controlled comparison of the effects of furosemide and hydrochlorothiazide added to propranolol in the treatment of hypertension. ( Dombey, SL; Lawrence, J; Vander Elst, E; Vlassak, W, 1981)
"Minoxidil has been administered to 16 patients with severe hypertension and renal failure."	5.04	Minoxidil in severe hypertension. ( Mäkelä, M; Oka, M, 1978)
"The changes in plasma renin activity (PRA) during short-term salt depletion (and peroral furosemide on the first day) and after bolus injection of propranolol were compared to the change during long-term treatment with diuretic and with propranolol in 19 patients with benign primary hypertension."	5.04	Acute and long-term salt depletion and beta-blockade: plasma renin activity response and its relation to blood pressure reduction in long-term treatment. ( Hesse, B; Nielsen, I; Steiness, E, 1978)
"Effect of long-term administration of propranolol was studied in 90 unselected patients with essential hypertension."	5.04	[Treatment of essential hypertension with propranolol (author's transl)]. ( Braun, B; Klaus, D; Klumpp, F; Lemke, R; Zehner, J, 1976)
"The effects of various levels of sodium intake and loop diuretic (furosemide) administration upon arterial pressure and renal function were studied in 11 patients with impaired renal function and essential hypertension."	5.04	Sodium intake and furosemide administration in hypertensive patients with renal insufficiency. ( Davidov, ME; Finnerty, FA; Moir, D; Mroczek, WJ, 1977)
"This study was designed to compare the effectiveness of spironolactone, hydrochlorothiazide, and combined spironolactone-hydrochlorothiazide therapy in patients with low renin and those with normal renin essential hypertension."	5.04	Diuretic therapies in low renin and normal renin essential hypertension. ( Brooks, CS; Johnson, CA; Kotchen, JM; Kotchen, TA, 1977)
"Furosemide and hydrochlorothiazide were compared for treatment of black patients with mild to moderate hypertension in a randomized, open-label, crossover study design."	5.04	Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients. ( Gomez-Sanchez, CE; Holland, OB; Kuhnert, LV; Pak, CY; Poindexter, C, 1979)
" Group A: In 14 patients with essential hypertension on chlorthalidone treatment, an additional daily dose of 640 mg propranolol for two months led to a significant reduction of the MAP (from 124 to 105 mm Hg) and PRA (from 5."	5.04	Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension. ( Boer, P; Geyskes, GG; Leenen, FH; Mees, EJ; Vos, J, 1975)
"Furosemide and the prostaglandin synthetase inhibitor, indomethacin, were administered singly and in combination to four normal subjects and six patients with essential hypertension in order to determine whether the antihypertensive, natriuretic and other effects of furosemide could be altered by inhibition of prostaglandin synthesis."	5.04	Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. ( Babej, M; Bentzel, CJ; Hysert, PE; Lee, JB; Mookerjee, BK; Patak, RV, 1975)
" While sulfonamide antibiotics are frequently implicated as causative agents for DRESS syndrome, furosemide, a nonantibiotic sulfonamide, has not been routinely reported as the causative agent despite its widespread use."	4.98	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature. ( Dumic, I; James, J; Nordin, TA; Sammour, YM; Virata, AR, 2018)
"Furosemide (frusemide) is a potent loop diuretic used in the treatment of oedematous states associated with cardiac, renal and hepatic failure, and for the treatment of hypertension."	4.78	Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). ( Ponto, LL; Schoenwald, RD, 1990)
"Activity of the circulating renin-angiotensin-aldosterone system (RAAS) has not been comprehensively characterized in cats with systemic hypertension (SH) or cardiomyopathy (CM), and the effects of furosemide or amlodipine treatment on the RAAS have not been fully evaluated in cats."	4.12	Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. ( Domenig, O; Guillot, E; Mochel, JP; Ward, JL; Ware, WA; Yuan, L, 2022)
"Furosemide is a loop diuretic drug frequently indicated in hypertension and fluid overload conditions such as congestive heart failure and hepatic cirrhosis."	3.85	Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions. ( Kodati, D; Yellu, N, 2017)
"We have previously shown that an association of losartan and hydrochlorothiazide, initiated 1 mo after 5/6 nephrectomy (Nx), reversed hypertension and albuminuria and promoted lasting renoprotection."	3.83	An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney. ( Arias, SC; Fanelli, C; Fujihara, CK; Malheiros, DM; Souza, RA; Zatz, R, 2016)
"Eligible participants included 54,721 female nurses aged 48 to 73 years in 1994 who provided information on thiazide diuretic and furosemide use in 1994, answered the question on hearing loss over their lifetime in 2012, and did not report hearing loss with date of onset before date of onset of hypertension diagnosis or medication use."	3.83	Hypertension, Diuretic Use, and Risk of Hearing Loss. ( Curhan, GC; Curhan, SG; Eavey, R; Lin, BM; Stankovic, KM; Wang, M, 2016)
"Experiments were carried out to investigate whether diuretics (hydrochlorothiazide + furosemide) impact on the effects of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor on glucose metabolism and blood pressure (BP) in metabolic syndrome SHR/NDmcr-cp(+/+) rats (SHRcp)."	3.83	Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. ( Fujisawa, Y; Hitomi, H; Kittikulsuth, W; Nakano, D; Nishiyama, A; Rafiq, K; Rahman, A; Sohara, E; Sufiun, A; Uchida, S, 2016)
"In a large longitudinal prospective cohort study of mostly older white women, a history of hypertension and use of furosemide were associated with a significantly higher risk of developing P-HPTH."	3.81	Hypertension, Antihypertensive Medications, and Risk of Incident Primary Hyperparathyroidism. ( Curhan, GC; Kronenberg, H; Paik, JM; Taylor, EN; Vaidya, A, 2015)
"Kidney-specific induction of heme oxygenase-1 (HO-1) attenuates the development of angiotensin II (Ang II) -dependent hypertension, but the relative contribution of vascular versus tubular induction of HO-1 is unknown."	3.78	Expression of heme oxygenase-1 in thick ascending loop of henle attenuates angiotensin II-dependent hypertension. ( Abraham, NG; Csongradi, E; Drummond, HA; Gousette, MU; Stec, DE; Storm, MV, 2012)
" HF-fed rats had impaired glucose tolerance, increased urine excretion of 8-isoprostane (a marker of oxidative stress), increased protein levels for NKCC2 (50-125%) and the renal outer medullary potassium channel (106%), as well as increased natriuretic response to furosemide (20-40%)."	3.75	Abundance of the Na-K-2Cl cotransporter NKCC2 is increased by high-fat feeding in Fischer 344 X Brown Norway (F1) rats. ( Ecelbarger, CM; Rash, A; Riazi, S; Sharma, N; Tiwari, S, 2009)
"Diastolic heart failure patients (n = 183) were more likely to be older, female, hypertensive, obese, with shorter preexisting HF duration, atrial fibrillation, lower New York Heart Association (NYHA) class, lower maintenance furosemide dosages, and to receive calcium antagonists."	3.75	Clinical variables affecting survival in patients with decompensated diastolic versus systolic heart failure. ( Almoznino-Sarafian, D; Alon, I; Babakin, Z; Cohen, N; Efrati, S; Gorelik, O; Modai, D; Shteinshnaider, M; Sokolsky, I; Tzur, I, 2009)
"In order to determine how both diuretics affect water metabolism, we here compare the effects of a rechallenge with either amiloride-hydrochlorothiazide fixed association (AmHTZ; amiloride chlorhydrate 5 mg+hydrochlorothiazide 50 mg; Moduretic) or furosemide (F; 40 mg; Lasix) on water excretion in a 79 year old woman who was previously admitted for severe symptomatic hyponatremia secondary to a 5 days course of AmHTZ for systolic hypertension."	3.75	Safety of furosemide administration in an elderly woman recovered from thiazide-induced hyponatremia. ( Cogan, E; Fadel, S; Karmali, R, 2009)
"Hypertension, renal dysfunction and furosemide administration at hospital admission are predictors of WRF among hospitalized patients."	3.75	Predictors of "worsening renal function" in patients hospitalized in internal medicine department. ( Al-Jabi, SW; Jayousi, HM; Sawalha, AF; Sweileh, WM; Zyoud, SH, 2009)
" He regularly took furosemide and ACE inhibitors for hypertension."	3.72	[Simulation of a colon carcinoma: diuretic-induced ulcerative-stricturing ischemic colitis]. ( Jonas, S; Kleespies, A; Neuhaus, P, 2004)
" This led to an increase in diagnoses of primary aldosteronism (PA) (confirmed by captopril-loading test)."	3.70	Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. ( Nishikawa, T; Omura, M, 2000)
"A 66-year-old hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure was treated by adding enalapril, an angiotensin converting enzyme inhibitor, to the furosemide and nifedipine regimen because of an insufficient antihypertensive response for 1 month."	3.69	Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure. ( Azukizawa, S; Kaneko, M; Kigoshi, T; Matsui, A; Morimoto, S; Nakano, S; Uchida, K, 1994)
"The relationship between renin responsiveness to furosemide and the antihypertensive effect of captopril in patients with normal-renin essential hypertension were studied in 23 patients including nine men (mean age, 41 years) and 14 women (mean age, 40 years)."	3.68	Correlation between renin responsiveness to furosemide and antihypertensive effect of captopril in patients with normal-renin essential hypertension. ( Chen, YM; Chu, TS; Fang, CC; Hsieh, BS, 1993)
"A 49-year-old man with liver cirrhosis and hypertension was found to have hyperkalemia out of a degree of renal insufficiency and metabolic acidosis with low to normal anion gap, aggravated by volume contraction with diarrhea and medications (captopril, spironolactone and atenolol) interfering with potassium homeostasis."	3.68	Hyperkalemia due to hyporeninemic hypoaldosteronism with liver cirrhosis and hypertension. ( Ahn, YH; Chang, DK; Choi, JW; Kee, CS; Kim, HJ, 1993)
"Patients with essential hypertension (n = 2969) who had not been taking any blood pressure medication for longer than 1 week were classified as furosemide-sensitive (FS) if their diastolic BP after furosemide fell > or = 10% and furosemide-resistant (FR) if it fell less than that."	3.68	Increased prevalence of cardiovascular complications in women with furosemide resistant essential hypertension. ( Anderson, GH; Blakeman, N; Newman-Palmer, N; Streeten, DH, 1993)
" In 10 patients with essential hypertension, we investigated the influence of betaxolol, a selective beta 1-adrenergic blocking agent, on renal function and on plasma levels of ANP during exercise, volume depletion and volume expansion."	3.68	Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. ( Grabensee, B; Heering, P; Hollenbeck, M; Kutkuhn, B; Plum, J, 1991)
"Plasma levels of atrial natriuretic peptide (ANP) were measured in patients with normal renin essential hypertension (n = 12), low renin essential hypertension (n = 11) and primary aldosteronism due to aldosterone producing adenoma (APA, n = 8) and idiopathic hyperaldosteronism (IHA, n = 3) after overnight rest in the supine position and after 4 h upright posture and furosemide administration."	3.68	Dissociation of plasma atrial natriuretic peptide responses to upright posture and furosemide administration in patients with normal-, low renin essential hypertension and primary aldosteronism. ( Fütö, L; Gláz, E; Gutkowska, J; Kiss, R; Rácz, K; Sergev, O; Varga, I, 1991)
"Acute responses of blood pressure and natriuresis to intravenous injection of furosemide and saline infusion were evaluated in 38 patients with essential hypertension."	3.68	Exaggerated natriuresis in salt-sensitive essential hypertension. ( Chen, YM; Chu, TS; Hsieh, BS; Tsai, HF; Wu, KD, 1990)
" furosemide administration in 10 offsprings of normotensive subjects who had a normal Na(+)-K+ cotransport activity and in 26 normotensive men with a positive family history of essential hypertension."	3.68	Vasoactive humoral systems and sodium transport in erythrocytes of normotensive offsprings of essential hypertensive subjects. ( Bultasová, H; Janata, V; Pinsker, P, 1990)
"The arterial pressure, the pulse frequency, the concentration of arterial natriuretic peptide (ANP), the aldosterone++ concentration and the plasma renin activity were determined in patients with primary hypertension after administration of furosemide in conditions of active assuming of erect position."	3.68	[Effects of 4-hour erect posture and furosemide on the blood level of atrial natriuretic peptide in patients with primary arterial hypertension]. ( Chlebus, H; Chodakowska, J; Ignatowska-Switalska, H; Januszewicz, A; Januszewicz, W; Lapiński, M; Stepniakowski, K; Wocial, B, 1990)
"This study investigated the ability of two diuretics, amiloride and frusemide, to prevent the development of ACTH induced hypertension in conscious sheep."	3.68	Amiloride blocks the onset of ACTH-induced hypertension in the sheep. ( Coghlan, JP; Reid, AF; Scoggins, BA; Whitworth, JA, 1990)
"Measurements of dopamine (DA) and its metabolites in plasma (DA sulfate) and urine (homovanillic acid) as well as its urinary response to furosemide revealed two distinct patterns: a hyperdopaminergic state in borderline essential hypertension (EH) and a renal DA deficiency in stable EH."	3.68	Peripheral dopamine in essential hypertension. An early defense against hypertension failing during its progression? ( Kuchel, O, 1990)
"Dynamic I-123 Hippuran renal studies to measure furosemide response (FR) were performed in three groups of patients: 1) 57 patients with renovascular hypertension due to a poststenotic, ischemic kidney; 2) 23 patients with essential hypertension; and 3) 50 nonhypertensive patients with healthy kidneys (control group)."	3.68	Diminished response to furosemide in I-123 Hippuran renal studies of renovascular hypertension caused by unilateral renal artery stenosis. ( Einspieler, R; Flueckiger, FM; Fueger, GF; Hausegger, K, 1990)
"Clinical, hemodynamic and neurohumoral data are available supporting the validity of a differentiated approach to administration of combined treatment with furosemide, digoxin and calcium antagonists nifedipine and verapamil in advanced-aged patients with hypertension complicated by circulatory disorders."	3.68	[Evaluation of the effectiveness of calcium antagonists combined with digoxin and furosemide in hypertension complicated by circulatory insufficiency in elderly patients]. ( Orynchak, MA, 1990)
"The article reports the efficacy and tolerability of a new slow-release formulation of furosemide (Lasix Retard) given to an elderly (mean: 72 years, range 48-92) population (n = 115, 77 females) suffering from hypertension or heart failure."	3.68	[Furosemide capsules in the treatment of hypertension or heart failure in the elderly in general practice]. ( Terland, O, 1990)
"The acute hemodynamic response to captopril (8 patients) and enalapril (8 patients) was evaluated in congestive heart failure patients in NYHA functional class III."	3.67	Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure. ( Enghoff, E; Hägg, A; Hedlund, A; Lantz, P, 1984)
"We studied the possible interplay between plasma bradykinin (P-BK) and the renin-angiotensin axis in essential hypertension, the effect of catecholamine on P-BK by standing and norepinephrine (NE) infusion, and the possible role of bradykinin in the hypotensive mechanism of angiotensin I converting enzyme inhibitor (captopril) in renin-independent essential hypertension."	3.67	[The effect of alterations of the renin-angiotensin system and the sympathetic nervous system on plasma bradykinin concentration in patients with essential hypertension]. ( Takeda, Y, 1984)
"We examined the urinary excretion of prostaglandin (PG)E2 and PGF2 alpha before and 15 min after stimulation with the acutely vasodilating agent furosemide in 25 normotensive controls and 81 patients with essential hypertension (EH)."	3.67	Prostaglandin excretion after furosemide in normal and low-renin essential hypertension. ( Scherer, B; Weber, PC; Witzgall, H, 1984)
"Studies were carried out in 15 patients with renal insufficiency and hypertension to compare the long-term effects of methyldopa and propranolol on renal hemodynamics."	3.67	Comparison of long-term renal hemodynamic effects of methyldopa and propranolol in patients with hypertension and renal insufficiency. ( Alterman, L; Bank, DE; Bank, N; Lowenstein, I; Zelen, R, 1984)
"In order to identify the hemodynamics of borderline essential hypertension, radionuclide angiography was performed before and after bolus injection of furosemide (40 mg i."	3.67	Hemodynamics in borderline hypertension: acute effect of furosemide. ( Barletta, GA; Bisi, G; Fabbri, G; Franchi, F; Malfanti, PL; Pedenovi, P; Scardi, A, 1984)
"Measures of maximal rates of lithium-sodium countertransport and frusemide-sensitive sodium and potassium cotransport have been proposed as biochemical markers for human essential hypertension."	3.67	The antihypertensive effect of calorie restriction in obese adolescents: dissociation of effects on erythrocyte countertransport and cotransport. ( Katch, VL; Rocchini, AP; Torretti, BA; Weder, AB, 1984)
" For this purpose, in a group of 11 patients with essential hypertension we have compared the blood pressure lowering effects of a single oral dose of nifedipine before (100 mmol Na+/day and 40 mmol K+/day) and after sodium depletion (20 mmol Na+/day and 40 mmol K+/day: each period was of 6-8 day duration)."	3.67	Effects of different sodium intakes on the antihypertensive and renal effects of single oral doses of nifedipine in hypertensive patients. ( Bolla, G; Cuspidi, C; Gradnik, R; Leonetti, G; Rupoli, L; Sangiorgio, P; Zanchetti, A, 1987)
"Our previous study demonstrated increased sodium (Na+) influx into ouabain-treated erythrocytes in diabetic patients with hypertension."	3.67	Increased furosemide-sensitive sodium influx into erythrocytes in non-insulin-dependent diabetes mellitus associated with hypertension. ( Chimori, K; Dodo, S; Goi, R; Goto, S; Hayashi, H; Izai, M; Miura, K; Miyazaki, S; Yasuda, K, 1989)
"Nifedipine, in a slow release preparation, was given at a mean daily dosage of 47 +/- 4 mg to 12 patients with severe hypertension in whom arterial pressure was not satisfactorily controlled (mean arterial pressure 132 +/- 4 4 mm Hg) by the combination of a converting enzyme inhibitor and a diuretic."	3.67	Effect of chronic nifedipine in patients inadequately controlled by a converting enzyme inhibitor and a diuretic. ( Mimran, A; Ribstein, J, 1985)
"As many as 52 patients with essential hypertension aggravated by circulatory failure were examined for the clinical, hemodynamic and neurohumoral parameters during furosemide stimulation."	3.67	[The efficacy of calcium antagonists in circulatory failure in elderly patients with hypertension]. ( Orynchak, MA, 1989)
"Twelve patients with essential hypertension receiving captopril monotherapy or captopril in conjunction with a diuretic had their 24-h blood pressure profiles monitored using an automatic, non-invasive ambulatory method."	3.67	Is captopril effective in controlling blood pressure when administered once daily? An assessment using 24-h ambulatory blood pressure monitoring. ( Buik, C; Frewin, DB; Rennie, G, 1989)
"Thirty patients with moderate to severe, uncontrolled hypertension were treated with a captopril/frusemide combination."	3.67	Low dose, twice daily captopril and frusemide: a safe, effective and flexible third line treatment regimen for hypertension. ( Corrie, J; Flapan, AD; Lindsay, BA; Padfield, PL; Rademaker, M, 1989)
"Fifty two patients with severe hypertension were treated with parentral chlorpromazine and frusemide."	3.67	Chlorpromazine and frusemide in the acute management of severe hypertension. ( Chikanza, IC; Okwanga, PN, 1989)
"In order to investigate the role of plasma angiotensin I (pAI) converting enzyme on the activity of the renin-angiotensin system, we measured plasma renin activity (PRA), plasma angiotensin II (pAII), and plasma angiotensin I converting enzyme (pACE) activity in fourteen patients with essential hypertension before and after two hours of ambulation combined with intravenous furosemide administration."	3.67	The role of plasma angiotensin I converting enzyme in regulation of renin-angiotensin system activity in patients with essential hypertension. ( Ando, T; Fukuyama, S; Hosoda, S; Ishida, H; Mori, Y; Nakagawa, H; Nishitani, T; Ogata, H; Shimamoto, K; Yokoyama, T, 1987)
"To provide information on the possible influence that hypertension or its treatment might have on the development of cysts in autosomal dominant polycystic kidney disease, we studied the effects of the sodium content of the diet, DOCA-salt hypertension, renovascular hypertension, and the administration of enalapril or furosemide on the development of 2-amino-4-5-diphenylthiazole (DPT)-induced renal cystic disease."	3.67	Mechanisms affecting the development of renal cystic disease induced by diphenylthiazole. ( Berndt, TJ; Carone, FA; Holley, KE; Knox, FG; Nesbit, JW; Okamura, M; Romero, JC; Torres, VE, 1988)
" In our study, we used enalapril, furosemide and verapamil for treatment of arterial hypertension in cardiac transplant recipients and investigated the influence of these drugs on ciclosporin whole blood trough levels."	3.67	[Effect of enalapril, furosemide and verapamil on cyclosporin concentration in whole blood]. ( Angermann, CE; Anthuber, M; Kemkes, BM; Spes, CH; Theisen, K, 1988)
"Nifedipine, in a slow release preparation, was given at a mean daily dosage of 47 +/- 4 mg to 12 patients with severe hypertension in whom arterial pressure was not satisfactorily controlled (mean blood pressure, 172 +/- 6/111 +/- 4 mmHg) by the association of a converting enzyme inhibitor and a diuretic."	3.67	Effect of nifedipine in hypertension not controlled by converting enzyme inhibitor and diuretic. ( Mimran, A; Ribstein, J, 1986)
"The purpose of this study was to define the effect of the angiotensin-converting enzyme inhibitor, enalapril maleate, on blood pressure, renal function, protein excretion, and potassium homeostasis in patients with hypertension associated with moderate to severe renal dysfunction."	3.67	Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. ( Bauer, JH; Reams, GP, 1986)
" Lasilactone, a new combination diuretic (furosemide 20 mg and spironolactone 50 mg) was evaluated in 30 patients with mild-to-moderate essential hypertension."	3.67	Efficacy and safety of lasilactone, a new combination diuretic, in essential hypertension. ( Birbari, AE; Daouk, MM; Mukaddam-Daher, S, 1987)
"Changes in plasma active and inactive renin and angiotensin II in response to tilt and intravenous frusemide were assessed in ten patients with essential hypertension, before treatment and again during chronic therapy with the alpha 1-adrenoceptor antagonist prazosin."	3.67	The effect of chronic prazosin therapy on the response of the renin-angiotensin system in patients with essential hypertension. ( Fulton, JD; Leckie, BJ; Malatino, LS; McAreavey, D; Morton, JJ; Murray, GD; Robertson, JI; Webb, DJ, 1987)
"The effect of captopril on renal plasma flow (RPF), glomerular filtration rate (GFR), plasma concentrations of renin, angiotensin II (Ang II), aldosterone (Aldo) and arginine vasopressin (AVP), serum osmolality (Sosm), free water clearance (CLH2O), fractional urinary excretion of electrolytes and blood pressure (BP), was examined in 10 patients with moderate essential hypertension."	3.67	Effect of captopril on renal haemodynamics and the renin-angiotensin-aldosterone and osmoregulatory systems in essential hypertension. ( Danielsen, H; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1986)
"Plasma concentrations of arginine vasopressin (AVP), angiotensin II (AII), aldosterone (Aldo), urinary output (V), osmolar clearance (Cosm), free water clearance (CH2O), fractional excretions of sodium (FENa) and potassium (FEK), urinary sodium excretion rate (U-Na) and serum potassium (S-K) were determined in 9 patients with essential hypertension (group I) and 13 normotensive healthy control subjects (group II) before and three times during the first 4 hours after an intravenous injection of 40 mg of furosemide."	3.67	Abnormal vasopressin and aldosterone response to furosemide in essential hypertension. ( Danielsen, H; Madsen, M; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1986)
" After favourable results obtained in a preliminary study using a combination of parenteral chlorpromazine and frusemide, a 5-year prospective study was conducted using this treatment to produce rapid reduction in blood pressure in patients with acute onset severe hypertension (blood pressure greater than 225/130 mmHg)."	3.67	Parenteral chlorpromazine and frusemide: safe and effective treatment for hypertensive emergencies. ( Lawson, AA; Nimmo, GR, 1986)
"10 patients with severe refractory hypertension were treated with captopril and frusemide."	3.66	Captopril and frusemide in severe drug-resistant hypertension. ( Ledingham, JG; Rajagopalan, B; White, NJ; Yahaya, H, 1980)
"Twenty patients with severe hypertension and chronic renal failure were given Captopril during a one year period."	3.66	[Long-term treatment with captopril in arterial hypertension complicated by renal failure]. ( Ader, JL; Bories, P; Durand, D; Emal, V; Girolami, JP; Suc, JM, 1982)
"14 patients with refractory hypertension did not respond either to captopril, an angiotensin II converting enzyme inhibitor, combined with a diuretic, a beta-blocker and hydralazine or minoxidil, a potent vasodilator, but they did respond to the combination of captopril, minoxidil, furosemide and a beta-blocker."	3.66	Captopril combined with minoxidil, beta-blocker and furosemide in the treatment of refractory hypertension. ( Rawat, R; Seedat, YK, 1983)
"Heart rate (HR), blood pressure and systolic time intervals (STI), including total electromechanical systole (QS2), left ventricular ejection time (LVETc), pre-ejection period (PEPc), the PEP/LVET index and the time to the peak of carotid upstroke (Ut), were measured in 24 patients with moderate essential hypertension after 15 days of treatment with oral furosemide (F), hydrochlorothiazide (H), propranolol (P), atenolol (A), furosemide + propranolol (F + P) and hydrochlorothiazide + propranolol (H + P)."	3.66	Modification of blood pressure and systolic time intervals by diuretics and beta-blockers in essential hypertension. ( Gamio Capestany, F; García-Barreto, D; González-Gómez, A; Hernández-Cañero, A, 1983)
"Five patients presenting with severe hypertension who failed to exhibit diastolic blood pressures less than 120 mm Hg following the oral administration of propranolol (60--80 mg) and furosemide (40 mg) received minoxidil (20 mg, p."	3.66	Rapid reduction of severe hypertension with minoxidil. ( Alpert, MA; Bauer, JH, 1980)
" This possibility was investigated by studying the influence of hydrochlorothiazide on blood pressure and urinary kallikrein excretion in patients with essential hypertension."	3.66	Interactions of diuretics with the renal kallikrein-kinin and prostaglandin systems. ( Higuchi, M; Kolloch, R; Müller, HM; Overlack, A; Stumpe, KO, 1982)
"During 12-week hydrochlorothiazide treatment 16 men suffering from uncomplicated essential hypertension were examined."	3.66	[Hemodynamic mechanism of the hypotensive action of diuretics and their effect on myocardial hypertrophy in the process of long-term treatment of hypertension]. ( D'iakonova, EG; Iurenev, AP, 1982)
"This paper reports the effect of frusemide given in therapeutic doses for hypertension in patients receiving prophylactic lithium for affective disorders."	3.66	Frusemide: a safe diuretic during lithium therapy? ( Coppen, A; Saffer, D, 1983)
" Pump activity appears higher and furosemide or bumetanide sensitive Na+ efflux lower in SHR compared to WKY suggesting a similar abnormality in SHR genetic hypertension as in human hypertension."	3.66	Furosemide and bumetanide-sensitive Na+ fluxes in erythrocytes from genetically hypertensive rats (SHR). ( De Mendonca, M; Garay, R; Grichois, ML; Herubel, A; Knorr, A; Meyer, P; Toumi, K, 1981)
"The humoral and hemodynamic effects of converting enzyme inhibition captopril are presented in two patients with primary hyperaldosteronism (PHA)."	3.66	Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism. ( Demers, LM; Harrison, TS; Hayes, AH; Luderer, JR, 1982)
"Alterations in the concentration of plasma dehydroepiandrosterone sulfate (DHEA-S) and cortisol in patients with essential hypertension (EH) were investigated."	3.66	A study on dehydroepiandrosterone sulfate in patients with essential hypertension. ( Hatano, M; Honda, M; Tsuchiya, M, 1982)
"The response of plasma renin activity (PRA), plasma aldosterone, 18-hydroxycorticosterone (18-OH-B), 18-hydroxydeoxycorticosterone (18-OH-DOC) and corticosterone to furosemide were compared in 20 normal control subjects, 16 patients with normal-renin essential hypertension (NREH) and 12 patients with low-renin essential hypertension (LREH)."	3.66	Rapid increase of mineralocorticoids after furosemide in low-renin essential hypertension: evidence for 18-hydroxycorticosterone to be a better marker than aldosterone. ( Thayil, G; Weber, PC; Witzgall, H, 1982)
"To assess the pathophysiological role of renal prostaglandin E (PGE) in renin subgroups of essential hypertension, urinary excretion of PGE before (24 hours urine) and after the administration of furosemide (1 mg/kg, iv) and 2 hours upright posture was estimated in 66 essential hypertensives, classified into high, normal and low renin subgroups."	3.66	Prostaglandin E synthesis in the kidney in renin subgroups of essential hypertension. ( Abe, K; Chiba, S; Haruyama, T; Hiwatari, M; Kasai, Y; Sato, K; Sato, M; Seino, M; Tajima, J; Yasujima, M; Yoshinaga, K, 1982)
"The 24-h urinary excretion of prostaglandins (PG) E2 and F2 alpha, which reflects the renal synthesis of these substances, was measured by radioimmunoassay in 10 patients with essential hypertension before and after treatment with propranolol."	3.66	Effect of propranolol treatment on the urinary excretion of prostaglandins E2 and F2 alpha in patients with essential hypertension. ( Bernheim, J; Rathaus, M, 1982)
"Plasma antidiuretic hormone (ADH) was measured before and after furosemide administration in hypertensive patients (essential benign hypertensions with low plasma renin activity) and in normal subjects."	3.66	Effects of furosemide-induced plasma volume reduction on plasma antidiuretic hormone in normal and hypertensive subjects. ( Ardaillou, R; Beaufils, M; Caillens, H; De Lima, J, 1981)
"The effect of age on the levels of active and trypsin-activatable inactive plasma renin was examined in 41 normal subjects and 54 patients with essential hypertension, during recumbency and after stimulation with furosemide and ambulation."	3.66	Effect of age on active and inactive plasma renin in normal subjects and in patients with essential hypertension. ( Hata, T; Higaki, J; Iwanaga, K; Kumahara, Y; Maruyama, A; Mikami, H; Murakami, K; Naka, T; Nakamaru, M; Ogihara, T, 1981)
"26 patients with severe hypertension (10 essential, 9 renal parenchymatous, 7 renovascular) and a mean age of 42 years were treated with the new oral converting enzyme inhibitor captopril (SQ 14225)."	3.66	[Captopril in treatment-resistant hypertension (author's transl)]. ( Lüscher, T; Siegenthaler, W; Studer, A; Vetter, W, 1980)
"To investigate the pathogenic role of the sympathetic nervous system and the renin-angiotensin system in essential hypertension, we evaluated plasma catecholamine and PRA levels after glucagon stimulation and during one hour in upright posture after i."	3.66	[Response of plasma catecholamine and PRA to i.v. injection of glucagon in upright posture after furosemide injection in essential hypertension (author's transl)]. ( Uda, M, 1981)
"The effect of age on active and cryoactivatable inactive plasma renin levels was examined in 58 normal subjects and 58 patients with essential hypertension during recumbency and after stimulation with furosemide and ambulation."	3.66	The effect of age on active and cryoactivatable inactive plasma renin in normal subjects and patients with essential hypertension. ( Hata, T; Iwanaga, K; Kumahara, Y; Maruyama, A; Mikami, H; Naka, T; Nakamaru, M; Ogihara, T, 1981)
"One hundred fifty eight patients with essential hypertension (both in- and out-patients) at stages IIA and IIB were treated with diuretics: furosemide (120 mg/day) during three days followed by hydrochlorothiazide in the doses that allow maintaining the renal sodium and water transport of the changed level."	3.66	[Continuous long-term treatment with diuretics of hypertension and the status of the renin-angiotensin-aldosterone system]. ( Konstantinov, EN; Mergenbaeva, TK; Nekrasova, AA; Ostapenko, TV; Suvorov, IuI, 1982)
"In an open multi-centre study, 51 patients with mild to moderate hypertension were treated with either a single dose of 40 mg penbutolol per day for 8 weeks or changed over at 4 weeks due to inadequate response with penbutolol alone to a single dose (1 tablet) of a fixed combination of 40 mg penbutolol and 20 mg furosemide per day for a further 4 weeks."	3.66	Efficacy of penbutolol and a fixed combination of penbutolol with furosemide in the treatment of hypertension. ( Graml, W; Haeringer, E; Rangoonwala, B; Roessner, M, 1982)
"Male and female, Sprague-Dawley rats, with and without arteriosclerosis, were subjected to chronic treatment with furosemide for 4 weeks."	3.66	Furosemide-induced hyperuricemia, hyperglycemia, hypertension and arterial lesions in nonarteriosclerotic and arteriosclerotic rats. ( Wexler, BC, 1981)
"Eighty-seven patients with intractable hypertension received minoxidil for a mean duration of 27 months (range three months to five years)."	3.66	Minoxidil in the management of intractable hypertension. ( Fife, R; Henderson, I; Isles, C; Kennedy, AC; Mackay, A, 1981)
"8 years) with a therapy-resistant hypertension were for 10 days treated with injections of diazoxide and furosemide (hypertonalum and furesis)."	3.66	[Changes in plasma volume and electrolytes after treatment of therapy-resistant hypertension with diazoxide and furosemide]. ( Cebulla, P; Herrmann, RM; Kiesewetter, R; Stoll, W, 1981)
" injection of furosemide in 10 normal subjects and in 10 patients with essential hypertension."	3.66	Effect of furosemide on renal prostaglandins E2 and F2 alpha in normal subjects and in patients with essential hypertension. ( Bauminger, S; Bernheim, J; Rathaus, M, 1980)
"Two groups of 10 patients with systemic arterial hypertension were studied by respiratory function tests before and after acute administration of diazoxide or furosemide."	3.66	Systemic arterial hypertension and small airways function: acute effects of diazoxide and furosemide. ( Accatino, G; Bucca, C; Galeasso, B; Pecchio, O; Ratti, C; Rolla, G, 1980)
"In patients with hypertension resistant to three or four drugs including a thiazide diuretic substitution of frusemide for the thiazide, or the addition of spironolactone, produced significant reductions in blood pressure and body weight."	3.66	Diuretic treatment of resistant hypertension. ( Freestone, S; Ramsay, LE; Silas, JH, 1980)
"Plasma concentrations of angiotensin II (AII), aldosterone, 18-hydroxycorticosterone and cortisol were measured in seven patients with benign essential hypertension and in seven age-matched control subjects before, and at frequent intervals for 2 h after the intravenous injection of frusemide (40 mg)."	3.66	Increased 18-hydroxycorticosterone responses to frusemide in essential hypertension. ( Fraser, R; Mason, PA; Semple, PF, 1980)
"Pericardial effusions are occasionally observed in patients treated with the new oral vasodilator, minoxidil."	3.66	Pericardial effusion associated with minoxidil therapy. ( Chatterjee, K; Houston, MC; McChesney, JA, 1981)
"To differentiate diuretic and direct cardiocirculatory properties of furosemide for elucidation of the vasodepressor mechanisms of action of the agent in the acute treatment of hypertension, the peripheral vascular effects of intravenous furosemide (3 mg/kg) on supine blood pressure (BP) and forearm hemodynamics in 11 functionally anephric hypertensive patients (creatinine clearance less than 2 ml/min) were studied."	3.66	Mechanisms of hemodynamic actions of furosemide: differentiation of vascular and renal effects on blood pressure in functionally anephric hypertensive patients. ( Katz, MA; Michael, UF; Mukherjee, SK; Ogden, DA, 1981)
"4 patients with hypertensive crisis (glomerulonephritis [n = 2], phaeochromocytoma [n = 1], reno-vascular hypertension [n = 1] combined with encephalopathy, showed a normalisation of blood-pressure up to 18 days during angiotensin-II-blockade with saralasin."	3.66	[Saralasin in resistant hypertensive crisis (author's transl)]. ( Heidland, A; Röckel, A, 1979)
"In order to investigate the role of 18-hydroxy-11-deoxycorticosterone (18-OH-DOC) in essential hypertension (EH), the responses of plasma 17-OH-DOC to 7 stimulation tests (furosemide test, adrenal suppression test, angiotensin II infusion test, adrenal stimulation test, metopirone test, saline infusion test and potassium chloride infusion test) and the circadian rhythm were investigated in 18 patients with essential hypertension (low renin group: 8, and normal renin group: 10)."	3.66	Plasma levels of 18-hydroxy-11-deoxycorticosterone in essential hypertension. ( Den, K; Hatano, M; Honda, M; Izumi, Y; Kanbegawa, A; Oguri, K; Shiratsuchi, T; Tsuchiya, M; Ueda, Y, 1978)
"Peripheral beta-adrenergic receptor sensitivity was characterized in 24 patients with essential hypertension and in 13 age-matched normotensive subjects using an isoproterenol hydrochloride bolus dose-response technique."	3.66	Peripheral beta-receptor responsiveness in patients with essential hypertension. ( Dominic, JA; Guthrie, GP; Kotchen, TA; Love, DW; McAllister, RG, 1979)
"In a controlled study of 11 women, 5 with mild essential hypertension and 6 normal volunteers, furosemide produced a significant natriuresis and diuresis without changes in the urinary excretion of prostaglandin E-like material and kallikrein."	3.66	Urinary excretion of prostaglandin E like material and kallikrein: effects of furosemide. ( Allen, H; Conradi, EC; Halushka, PV; Margolius, HS, 1979)
"In essential hypertension mean basal (supine) and stimulated plasma renin activity (2 h upright posture + 40 mg furosemide intraveneously) decreased progressively with age."	3.66	Age- and sex-related differences in plasma aldosterone in essential hypertension. Relationship to plasma renin activity. ( Alasso, I; Glänzer, K; Vetter, H; Vetter, W, 1979)
"Plasma concentrations of angiotensin II (AII) were studied in 36 patients with primary (essential) hypertension and 15 normotensive control subjects during basal (1 h supine rest), upright and frusemide-stimulated (80 mg orally) conditions."	3.66	Angiotensin II in primary hypertension, relationship to plasma renin activity, aldosterone and urinary electrolytes. ( Karlberg, BE; Tolagen, K, 1979)
"Twenty-four patients with hypertension were treated with chlorothiazide, chlorthalidone, and frusemide."	3.66	Duration of effect of different diuretics. ( Adam, WR; Hodgson, N; Morgan, TO; Myers, J, 1979)
"Fifty-six patients with essential hypertension and 29 normotensive controls were hospitalized and volume expanded with saline or volume depleted with furosemide."	3.66	Effect of acute volume alterations on norepinephrine and dopamine-beta-hydroxylase in normotensive and hypertensive subjects. ( Lake, CR; Ziegler, MG, 1978)
"In two patients with severe hypertension and moderately severe renal insufficiency, metolazone and furosemide were used in combination with propranolol, methyldopa, and hydralazine to augment control of blood pressure."	3.66	Severe electrolyte disturbances associated with metolazone and furosemide. ( Black, WD; Roman, J; Shiner, PT, 1978)
"The effect of furosemide on urinary kallikrein excretion was studied in 10 patients with essential hypertension and 9 normal volunteer subjects."	3.66	Effect of furosemide on urinary kallikrein excretion in patients with essential hypertension. ( Abe, K; Chiba, S; Irokawa, N; Ito, T; Kusaka, T; Miyazaki, S; Ritz, K; Saito, K; Sakurai, Y; Seino, M; Yasujima, M; Yoshinaga, K, 1978)
"Seventy-nine patients with essential hypertension were evaluated for peripheral renin activity in response to injection of 60 mg of furosemide and to upright posture."	3.66	The multiple factors affecting plasma renin activity in essential hypertension. ( Corder, CN; McDonald, RH; Shuman, J; Vagnucci, AH, 1978)
"Studies were undertaken to determine if the dissociation of aldosterone and plasma renin activity in low-renin essential hypertension is due to altered adrenal responsiveness to angiotensin II."	3.66	Increased adrenal sensitivity to angiotensin II in low-renin essential hypertension. ( Brown, RD; Wisgerhof, M, 1978)
"To study whether the renin-angiotensin system is related to hyperuricemia in hypertension, the serum concentration of uric acid was determined in 96 patients with various types of hypertension and various degrees of plasma renin activity (PRA)."	3.66	Serum uric acid and the renin-angiotensin system in hypertension. ( Kato, E; Kondo, K; Nakamura, R; Oguro, T; Ozawa, Y; Saito, I; Saruta, T; Yamagami, K, 1978)
" in 1975 revealed that the antihypertensive and natriuretic effects of furosemide were markedly blunted or abrogated by indomethacin in both normotensive and hypertensive man, it has been postulated that the ameliorative effects of furosemide in human essential hypertension might be mediated by release of intrarenal prostaglandins."	3.66	Antihypertensive effect of volume depletion: interrelation with renal prostaglandins. ( Attallah, A; Braselton, WE; Düsing, R; Lee, JB, 1978)
"Eleven patients with hypertension secondary to renal disease were treated with hydrochlorothiazide or furosemide plus other drugs to normalize blood pressure."	3.66	Use of diuretics in treatment of hypertension secondary to renal disease. ( Bank, N; Lief, PD; Piczon, O, 1978)
"Minoxidil-induced sequential changes in plasma renin activity, urinary aldosterone and norepinephrine excretion were assessed in 11 patients with severe hypertension receiving propranolol or oxprenolol, chlorthalidone and spironolactone."	3.66	[Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers]. ( Brunner, HR; Ferguson, RK; Gavras, H; Jaeger, P; Jéquier, E; Turini, GA, 1978)
"By a combined vasodilator-[diisopropylamine (disostat), dihydralazine (depressan)] furosemide- (furesis-) infusion therapy was tried to achieve a new stabilisation of the blood pressure of therapy-refractory patients with hypertension."	3.66	[Drug-induced readjustment of therapy-resistant hypertension]. ( Herrmann, R; Kiesewetter, R, 1978)
"The possibility has been explored of using a specific angiotensin ii antagonist, saralasin (P-113, 1-sar-8-ala-angiotensin ii) to recognize patients whose hypertension depends upon excessive angiotensin ii activity."	3.65	Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;. ( Anderson, GH; Dalakos, TG; Freiberg, JM; Streeten, DH, 1975)
" Propranolol and furosemide were administered concomitantly to control reflex tachycardia and fluid retention."	3.65	The outpatient treatment of refractory hypertension with minoxidil. ( Ball, JH; Kleiner, JP; Nelson, WP; Norton, JD, 1977)
"Urinary excretion of prostaglandin E was measured radioimmunologically in 19 healthy persons (15 men and 4 women) and in 16 patients (10 men and 6 women) with essential hypertension before and after the administration of furosemide."	3.65	Effect of furosemide on urinary excretion of prostaglandin E in normal volunteers and patients with essential hypertension. ( Abe, K; Chiba, S; Irokawa, N; Ito, T; Saito, T; Yasujima, M; Yoshinaga, K, 1977)
"To identify patients with low-renin hypertension, we measured plasma renin activity after the administration of 40 mg of furosemide intravenously and 30 minutes of upright posture in 127 normotensive subjects and 363 patients with essential hypertension."	3.65	The intravenous furosemide test: a simple way to evaluate renin responsiveness. ( Gomez-Sanchez, C; Higgins, J; Holland, OB; Kaplan, NM; Kem, DC; Kramer, NJ, 1976)
"An understanding of the possible role of excessive angiotensin II activity in the pathogenesis of hypertension in every patient is therapeutically desirable, but it is frustrated by the lack of complete reliability of peripheral plasma measurements of renin activity."	3.65	Angiotensin blockade: its clinical significance. ( Anderson, GH; Dalakos, TH; Streeten, DH, 1976)
"The response of plasma renin concentration [PRC] to Furosemide administration and orthostasis stimulation was studied in 9 healthy volunteers and in 30 patients with essential hypertension."	3.65	The effect of furosemide stimulation on renin secretion and its application in examining activity of the renin-angiotensin system. ( Zofková, I, 1976)
"Changes in arterial blood pressure, renal electrolyte excretion, and plasma renin activity in response to repeated doses of furosemide were measured in 12 patients with essential hypertension admitted to the medical service for electrolyte balance studies."	3.65	Furosemide and plasma renin activity in essential hypertension. ( Hutcheon, DE; Sandhu, R, 1976)
" In patients with mild or moderate essential hypertension, oral propranolol, given in incremental doses, produced a moderate but significant lowering of blood pressure which was correlated with the concentration of propranolol in plasma."	3.65	Hypotensive and renin-suppressing activities of propranolol in hypertensive patients. ( Bianchetti, G; Chidsey, CA; Di Salle, E; Leonetti, G; Mayer, G; Morganti, A; Morselli, PL; Terzoli, L; Zanchetti, A, 1975)
"To clarify the role of the enucleated adrenal in the suppression of plasma renin activity (PRA) in adrenal regeneration hypertension (ARH), PRA response to furosemide administration was compared at the 9th experimental week in three groups of rats, which had been subjected to (a) sham operation (control), (b) unilateral nephrectomy, (c) unilateral nephrectomy plus contralateral adrenal enucleation, and given on tap water or high sodium intakes."	3.65	Suppressed plasma renin activity in adrenal regeneration hypertension. ( Hasatani, K; Morimoto, S; Takeda, R, 1975)
"Plasma aldosterone, plasma renin activity, sodium and potassium in the plasma and the urine were determinated under acute stimulation with saline-depletion (furosemide) and under acute suppression with saline infusion in 40 patients with primary hypertension stage I, 19 patients with primary hypertension stages II and III, and 11 patients with renal hypertension (chronic glomerulonephritis and chronic pyelonephritis)."	3.65	[Plasma aldosterone and plasma renin activity in patients with essential and renal hypertension under acute stimulation with saline depletion and acute suppression with saline infusion]. ( Klaus, D; Klumpp, F; Lemke, R; Zehner, J; Zöfel, P, 1975)
"Thirteen patients with severe hypertension were treated with combined minoxidil, propranolol, and furosemide (mean daily doses 33 mg, 475 mg, and 578 mg, respectively) for nine to twenty-five months (mean 13."	3.65	Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide. ( Bennet, CM; Blaufuss, A; Wilburn, RL, 1975)
"Twenty-six patients were selected for treatment with minoxidil on the basis of hypertension which could not be controlled either because of (1) drug failures and/or (2) side effects of drugs."	3.65	Minoxidil in severe hypertension: value when conventional drugs have failed. ( Dormois, JC; Nies, AS; Young, JL, 1975)
"The anti-hypertensive effect of spironolactone and thiabutazide was tested on 47 unselected patients with primary hypertension."	3.65	[Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)]. ( Braun, B; Klaus, D; Klump, F; Lemke, R; Zehner, J; Zöfel, P, 1975)
"1) To clarify the role of adrenal enucleation on plasma renin activity (PRA), plasma renin substrate (PRS), PRA response to furosemide administration and vacular reaction to renin in adrenal regeneration hypertension (ARH), serial changes of PRA and PRS during adrenal regeneration, PRA response to furosemide administration, and pressor response to exogenous renin in ARH were investigated by comparison with those of intact rats, unilaterally adrenalectomized rats, and unilaterally nephroadrenalectomized rats with contralateral adrenalectomy or with contralateral adrenal exploration (control) on both tap water and high sodium intake."	3.65	[Studies on the renin-angiotensin system in adrenal regeneration hypertension (author's transl)]. ( Hasatani, K, 1975)
" In contradistinction, clonidine caused a dose-related hypotension in conscious unrestrained rats subjected to sodium depletion via furosemide."	3.65	Hypotensive effect of clonidine during sodium depletion in the rat. ( Pals, DT, 1975)
"Treatment with oral diazoxide for periods of 4 to 10 weeks in hospital allowed adequate control of hypertension with continuation of fetal growth in four patients with severe toxaemia."	3.65	Successful use of oral diazoxide in the treatment of severe toxaemia of pregnancy. ( Davis, D; Morgan, MY; Pohl, JE; Thurston, H, 1972)
" During the treatment all patients, except for those who were assigned to the control group, received Loop Diuretic Furosemide dosed at 20-30 mg per day and Solifenacin dosed at 5 mg per day (First comparison group) and 10 mg per day (Second comparison group)."	2.79	Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin. ( Ivanovskaya, MA; Kosilov, KV; Kosilova, LV; Loparev, SA, 2014)
" On long term evaluation in an open design (Phase II), wherein Phase I participants continued Terminalia Arjuna in fixed dosage (500 mg 8-hourly) in addition to flexible diuretic, vasodilator and digitalis dosage for 20-28 months (mean 24 months) on outpatient basis, patients showed continued improvement in symptoms, signs, effort tolerance and NYHA Class, with improvement in quality of life."	2.68	Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. ( Bharani, A; Bhargava, KD; Ganguly, A, 1995)
" All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12."	2.68	The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995)
"Orlistat was given in doses of 50 mg 3 times daily mid-meal for 7 (nifedipine and captopril) or 8 days (atenolol and furosemide)."	2.68	Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. ( Jonkmann, JH; Schmidtke-Schrezenmeier, G; Tam, YK; van Brummelen, P; Weber, C, 1996)
"Lacidipine was not very effective in controlling blood pressure and had an adverse effect on renal function."	2.68	Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency. ( Bailey, RR; Lynn, KL; Robson, RA; Shand, BI; Smith, AH, 1997)
"Ramipril 5 mg daily was effective in 55."	2.67	The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension. ( Carré, A; Vasmant, D; Zannad, F, 1992)
"Furosemide (20 mg) was injected intravenously in eight hypertensive subjects with pretreatment with captopril (25 mg) or matching placebo."	2.67	Influence of captopril on urinary excretion of furosemide in hypertensive subjects. ( Ebihara, A; Fujimura, A; Shimokawa, Y, 1990)
"Furosemide 20 mg was injected intravenously in eight hypertensive subjects already treated with oral captopril 25 mg or a matching placebo."	2.67	Effect of furosemide on angiotensin II-mediated prostaglandin I2 production in hypertensive subjects. ( Ebihara, A; Fujimura, A, 1990)
" The mean supine BP 24 hours post dosing were 177/110 mmHg (placebo), 173/109 mmHg (propranolol) and 164/100 mmHg (atenolol)."	2.66	Atenolol or propranolol in hypertensive patients poorly controlled on captopril and frusemide. ( Lovell, HG; Petrie, JC; Robb, OJ; Webster, J; Witte, K, 1987)
" It is concluded that a gradual fall in BP can be obtained after fractionated dosage of diazoxide (i."	2.66	Severe hypertension with cerebral symptoms treated with furosemide, fractionated diazoxide or dihydralazine. Danish Multicenter Study. ( Hilden, T; Krogsgaard, AR; McNair, A; Nielsen, PE, 1986)
"Treatment with labetalol alone or in combination with furosemide, as well as methyldopa plus furosemide, was associated with significant reductions in supine and standing blood pressure levels."	2.65	Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial. ( Langford, H; Maloy, J; Maronde, RF; Michelson, EL; Poland, M; Wallin, JD; Wilson, D; Winer, N, 1983)
"Patients with hypertension have abnormalities in renin release and renal vascular resistance that might be due to abnormalities in renal prostaglandin synthesis."	2.65	Responses to furosemide in normotensive and hypertensive subjects. ( Wilson, TW, 1983)
"Oxprenolol was the best tolerated drug, with only 5% of patients withdrawing due to side-effects compared to 13% on spironolacone and 29% on methyldopa."	2.64	Renin unresponsiveness and the effects of oxprenolol, methyldopa and spironolactone in pateints with essential hypertension. ( Beilin, LJ; Ledingham, JG; Thomas, GW; Yeates, KM, 1976)
" furosemide and bumetanide) and more reliable bioavailability (vs."	2.53	Loop Diuretics in the Treatment of Hypertension. ( Malha, L; Mann, SJ, 2016)
"Primary aldosteronism (PA) is a form of surgically curable secondary hypertension."	2.43	[Screening tests and diagnostic examinations of hypertensives for primary aldosteronism]. ( Nishikawa, T; Omura, M, 2006)
"Primary aldosteronism (PA) is the most common cause of endocrine hypertension."	1.91	Biochemical Evaluation by Confirmatory Tests after Unilateral Adrenalectomy for Primary Aldosteronism. ( Asari, Y; Daimon, M; Kageyama, K; Kinoshita, N; Murasawa, S; Nakada, Y; Takayasu, S; Usutani, M; Watanuki, Y, 2023)
"Furosemide was ranked 10th in OPP and 3rd in VOPP (2."	1.91	Comparison of primary care prescriptions for old and very old hypertensive patients. ( Akıcı, A; Ataç, Ö; Aydın, V; Çolak, ST; Kaşkal, M; Vızdıklar, C, 2023)
"Primary aldosteronism (PA) is a well-known cause of secondary hypertension."	1.91	Simple standing test without furosemide is useful in the diagnosis of primary aldosteronism. ( Fushimi, Y; Iwamoto, H; Iwamoto, Y; Kaku, K; Kaneto, H; Katakura, Y; Kimura, T; Kusano, T; Mune, T; Nakanishi, S; Ohnishi, M; Sanada, J; Shimoda, M; Takenouchi, H; Tatsumi, F, 2023)
"Congenital mesoblastic nephroma is a rare pediatric renal tumor and has been reported in patients presenting with palpable abdominal mass, arterial hypertension, hematuria, polyuria, or hypercalcemia."	1.72	Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma: A case report and management of neonatal hypercalcemia: Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma. ( Bacchetta, J; Bordet, F; Dijoud, F; Duncan, A; Mure, PY; Pracros, JP; Tanné, C, 2022)
"Hypertension is modeled as overactive renal sympathetic nervous activity."	1.72	Determining risk factors for triple whammy acute kidney injury. ( Layton, AT; Leete, J; López-Hernández, FJ; Wang, C, 2022)
"Hypertension is a chronic disease associated with chronic inflammation involving activated macrophages."	1.62	Captopril Combined with Furosemide or Hydrochlorothiazide Affects Macrophage Functions in Mouse Contact Hypersensitivity Response. ( Bryniarski, P; Marcinkiewicz, J; Nazimek, K, 2021)
" This patient's case highlights the need of further studies evaluating efficacy of repeated dosing of CCP."	1.62	Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient. ( Bloch, EM; Chua, F; Goel, R; Katz, LM; Mirihagalle, N; Parajuli, P; Prakash, V; Saha, D; Shah, A; Sundareshan, V; Tobian, AAR; Waqar, S, 2021)
"Furosemide was by far the most common diuretic given and the initial intravenous dose was only 20 mg in more than half of ICU admissions."	1.51	Patterns of diuretic use in the intensive care unit. ( Chang, TI; Chertow, GM; McCoy, IE, 2019)
"Arterial hypertension was the leading indication for furosemide (38."	1.48	[Evaluation of the prescription of furosemide in persons aged 75years and older in a geriatric acute-care unit]. ( Asgassou, S; Buttard, M; d'Athis, P; Deïdda, M; Dipanda, M; Laborde, C; Mahmoudi, R; Manckoundia, P; Pioro, L; Putot, A; Putot, S, 2018)
" Further efforts in this series led to the discovery of analogs with improved pharmacokinetic profiles."	1.43	Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold. ( Alonso-Galicia, M; Bailey, T; Brochu, RM; de Jesus, RK; Ding, FX; Ehrhart, J; Felix, JP; Garcia, ML; Gu, X; Ha, S; Hampton, C; Hernandez, M; Jiang, J; Kaczorowski, GJ; Owens, K; Pai, LY; Parmee, ER; Pasternak, A; Pio, B; Priest, BT; Roy, S; Shahripour, A; Sullivan, K; Swensen, AM; Tang, H; Teumelsan, N; Thomas-Fowlkes, B; Walsh, SP; Yang, L; Zhou, X; Zhu, Y, 2016)
"Hypertension is a major risk factor for atherogenesis and heart hypertrophy, both of which are associated with specific morphological and functional changes of the myocardium."	1.43	Furosemide modifies heart hypertrophy and glycosaminoglycan myocardium content in a rat model of neurogenic hypertension. ( Karakiulakis, G; Kouvelas, D; Manthou, ME; Papakonstantinou, E; Pourzitaki, C; Tsaousi, G, 2016)
"Echocardiography showed 73% dilated cardiomyopathy; 83% showed moderate to severe LV systolic dysfunction (mean EF 36."	1.43	Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti. ( Malebranche, R; Morisset, PH; Raphael, NA; Tabou Moyo, C; Wilentz, JR, 2016)
"Type 2 diabetic kidney disease (DKD) is frequently accompanied by uncontrollable hypertension due to the sodium sensitivity inherent in DKD and to diuretic-resistant edema."	1.42	Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. ( Hirai, K; Hoshino, T; Ito, K; Kaku, Y; Miyazawa, H; Mori, H; Ookawara, S; Tabei, K; Ueda, Y; Yoshida, I, 2015)
" A variety of adverse events (AEs) of varying severity have been noted during HPC infusions."	1.40	Infusion technique of hematopoietic progenitor cells and related adverse events (CME). ( Bryant, SC; Gastineau, DA; Greiner, CW; Hogan, WJ; Jacob, EK; Lingineni, RK; Mohr, A; Mulay, SB; Padley, D, 2014)
"Primary aldosteronism (PA) is common in young or middle-aged hypertensive patients, but PA among the elderly has recently become more common."	1.40	The influence of aging on the diagnosis of primary aldosteronism. ( Hongyo, K; Ito, N; Kamide, K; Kawai, T; Nakama, C; Onishi, M; Rakugi, H; Sugimoto, K; Takeya, Y; Yamamoto, K, 2014)
"In patients with congestive heart failure (CHF), use of loop diuretic therapy may result in acute kidney insufficiency (AKI)."	1.39	Predisposing factors for acute kidney injury in Hispanic patients treated with diuretics for decompensated heart failure. ( Cangiano, JL; López, JE; Marmorato, R; Pagán, P; Ramírez, T; Ricci, F; Soto-Salgado, M; Vega, J, 2013)
"Nitrates were given most often in pulmonary oedema and hypertensive AHF."	1.39	Management of acute heart failure and the effect of systolic blood pressure on the use of intravenous therapies. ( Harjola, VP; Lassus, J; Nieminen, MS; Siirilä-Waris, K; Tarvasmäki, T; Tolonen, J, 2013)
"Atherosclerotic renal artery stenosis has a range of manifestations depending on the severity of vascular occlusion."	1.37	Blood oxygen level-dependent magnetic resonance imaging identifies cortical hypoxia in severe renovascular disease. ( Crane, JA; Glockner, JF; Gloviczki, ML; Grande, JP; Lerman, LO; McKusick, MA; Misra, S; Textor, SC, 2011)
"Nitroglycerine was the most commonly used antihypertensive treatment overall (40% of patients), followed by urapidil (21%), clonidine (16%) and furosemide (8%)."	1.37	Characteristics, practice patterns, and outcomes in patients with acute hypertension: European registry for Studying the Treatment of Acute hyperTension (Euro-STAT). ( Anderson, FA; de La Garanderie, DP; Emery, L; Gore, JM; Rushton-Smith, S; Vincent, JL; Vuylsteke, A; Wyman, A, 2011)
"The cause for the hypertension is unknown."	1.35	Prenatal programming of rat thick ascending limb chloride transport by low-protein diet and dexamethasone. ( Baum, M; Dagan, A; Dwarakanath, V; Gattineni, J; Habib, S, 2009)
"Furosemide and torasemide induce a similar dose-response curve venodilation, but they have no effect on the arterial bed."	1.34	Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. ( de Berrazueta, JR; de Mier, I; García-Unzueta, MT; González, JP; Poveda, JJ, 2007)
"Only clonidine treatment totally prevented the development of insulin resistance, and high-dose aspirin, known to prevent insulin resistance by inhibition of the activity of IkappaB kinase-beta, decreased the degree of insulin resistance by almost 70%."	1.32	Hypertension and insulin resistance are not directly related in obese dogs. ( Gokee, A; Rocchini, AP; Yang, JQ, 2004)
"Anemia, hypertension and rheumatic fever were the causes of heart failure in these 3 patients, but they were not apparent when the initial diagnosis was made."	1.31	[Peripartum heart failure: the underestimated role of frequent diseases in the Sudan-Sahelian area]. ( Ba, SA; Dia, AA; Diop, IB; Diouf, SM; Kane, A; Sarr, M, 2000)
" The changes in the ETK (erythrocyte transketolase activity in whole blood) and a-ETK (ETK activity coefficient) during the hospital stay correlated with the cumulative dosage of furosemide adjusted for the duration of the therapy (r = 0."	1.31	Diuretic use: a risk for subclinical thiamine deficiency in elderly patients. ( Haller, J; Hany, A; Suter, PM; Vetter, W, 2000)
"Then furosemide treatment was stopped and the rat food was changed to 1% NaCl diet."	1.30	Effects of renal papillary-medullary lesion on the antihypertensive effect of furosemide and development of salt-sensitive hypertension in Dahl-S rats. ( Christensen, S; Haugan, K; Marcussen, N; Petersen, JS; Shalmi, M; Spannow, J, 1997)
"In furosemide-treated dogs, orally given SK-1080 produced a dose-dependent and long-lasting (>8 h) antihypertensive effect with a rapid onset of action (time to Emax, 1-1."	1.30	In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. ( Kwon, KJ; Lee, BH; Seo, HW; Shin, HS; Yoo, SE, 1999)
" A dose-response curve to Ang II was plotted for cumulative concentrations (from 10(-9) to 10(-6) mol/L) in endothelium-denuded aortic rings (pD(2)=7."	1.30	Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. ( Díez, J; Fortuño, A; Fortuño, MA; Muñiz, P; Ravassa, S; Rodriguez, JA; Zalba, G, 1999)
"Acute myocardial infarction is characterized by a more pronounced rise in plasma ANP concentration in hypertensive patients than in those without a history of hypertension."	1.29	Elevated plasma atrial natriuretic peptide concentrations in hypertensive patients with acute myocardial infarction. ( Górecki, A; Ignatowska-Switalska, H; Januszewicz, A; Kochanowski, J; Lapiński, M; Opolski, G; Stolarz, P; Słomka, K; Wocial, B, 1995)
"Furosemide (30 mg/kg) was given orally to each group at 12 a."	1.28	Influence of DOCA treatment on administration-time-dependent changes in the effects of furosemide in saline-loaded rats. ( Ebihara, A; Fujimura, A; Ohashi, K; Shiga, T; Sudoh, T, 1992)
"A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome."	1.28	Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome. ( Friedler, A; Mor, F; Shapira, Y; Weinberger, A; Wysenbeek, AJ, 1990)
" The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS)."	1.28	Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ( Aberg, J; Gelin, A; Karlberg, BE; Larsson, R; Regårdh, CG, 1990)
" The purpose of the present study was to examine whether long-term therapy with ramipril (RA, and ACE inhibitor) would lower blood pressure more effectively and without adverse reactions in combination with the loop diuretics piretanide (PI) or furosemide (FU)."	1.28	Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats. ( Baldes, L; Becker, RH; Treudler, M, 1989)
"Captopril was also able to reduce the proteinuria of non-diabetic glomerular origin."	1.28	Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans. ( Alcazar, JM; Gutierrez-Millet, V; Oliet, A; Praga, M; Rodicio, JL; Ruilope, LM, 1989)
" Chronic administration of 100-150mg of captopril tid caused no further blood pressure reduction."	1.27	Further studies on the hypernoradrenergic state of treated hypertensives: effect of captopril. ( Anderson, R; Gianotti, L; Kirk, L; Kuhnert, L; Matthews, C; Mitchell, HC; Pettinger, WA; Reed, G, 1983)
"Ozolinone is a loop diuretic with two isomers."	1.27	Effect of captopril on intrarenal blood flow. ( Giesen, EM; Imbs, JL; Schmidt, M; Schwartz, J, 1984)
" Of these, three patients who had started taking frusemide because of hypertension and one whose dosage of a reserpine combination drug had been increased experienced an appreciable decrease in blood pressure immediately after the stroke; they also showed signs of haemoconcentration."	1.27	Contribution of inappropriate treatment for hypertension to pathogenesis of stroke in the elderly. ( Gribnau, FW; Jansen, PA; Poels, EF; Schulte, BP, 1986)
") alone or in combination with furosemide (1 mg/kg, i."	1.27	The effects of acebutolol alone and in combination with furosemide or hydralazine in experimentally induced hypertensive G-minipigs. ( Hidaka, H; Sawada, S; Tanioka, Y; Yasuda, Y, 1986)
"Pretreatment with dihydralazine resulted in normalization of distribution coefficients (0."	1.27	Interactions of dihydralazine with furosemide in hypertonic patients. ( Biebler, KE; Donner, I; Franke, G; Kairies, M; Siegmund, W, 1987)
"These changes included acute disseminated intravascular coagulation, severe elevations of liver enzymes, severe renal dysfunction, and hemolytic anemia."	1.27	A case of postpartum hemolytic uremic syndrome with severe elevations of liver enzymes. ( Fujii, S; Kanzaki, H; Kariya, M; Matsuura, S; Mori, T; Sagawa, N, 1985)
"When furosemide was added to the ATF in a concentration of 0."	1.27	TGF-mediated oscillations in the proximal intratubular pressure: differences between spontaneously hypertensive rats and Wistar-Kyoto rats. ( Holstein-Rathlou, NH; Leyssac, PP, 1986)
" Torasemide was practically fully absorbed by the gastrointestinal tract, its bioavailability by oral route ranged from 80 to 100%."	1.27	Pharmacological properties of the new potent diuretic torasemide in rats and dogs. ( de Suray, JM; Delarge, J; Denef, J; Georges, A; Gerin, M; Ghys, A; Willems, J, 1985)
"In 17 patients with chronic renal failure treated by haemodialysis and with arterial hypertension, PRA was likewise determined before and after injecting furosemide."	1.26	Response of peripheral plasma renin activity (PRA) to furosemide stimulation; reduction of the renal parenchyma as a limiting factor. ( Rotnáglová, Z; Stríbrná, J; Zabka, J, 1981)
" A booster dosage of 5 to 20 mg of minoxidil was given at four hours if the diastolic BP exceeded 100 mm Hg."	1.26	Rapid control of severe hypertension with minoxidil. ( Alpert, MA; Bauer, JH, 1982)
"Screening tests for primary aldosteronism were compared in 22 patients with this disorder and 140 hypertensive controls."	1.26	Simplified screening procedures for primary aldosteronism. Studies on the mechanism of the hyper-responsiveness to furosemide and standing. ( Anderson, GH; Streeten, DH, 1982)
"Low-renin hypertension was diagnosed by the presence of hypertension, hypokalaemic alkalosis, suppressed plasma renin activity and low plasma aldosterone."	1.26	Low-renin, low-aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child. ( Fiselier, TJ; Honour, JW; Monnens, LA; Otten, BJ; van Munster, PJ, 1982)
"Minoxidil is an extremely potent hypotensive drug."	1.26	Minoxidil and labetalol: very effective antihypertensive combination. ( Bett, N; Boyle, P; Craswell, P; Whiting, G, 1980)
"The saralasin test was performed in 68 hypertensives."	1.26	[The saralasin test in the diagnosis of hypertension (author's transl)]. ( Bönner, G; Helber, A; Hummerich, W; Kaufmann, W; Meurer, KA; Wambach, G, 1979)
"The biguanides were a therapeutic enrichment particularly in the treatment of adipose elderly diabetics with obligatory diet."	1.26	[Indications and results of an additional differentiated pharmacotherapy of obesity]. ( Kucher, E, 1978)
" During another two-week period, a 50 mg/day dosage of hydrochlorothiazide did cause a significant rise in serum lithium levels."	1.26	Serum lithium levels and long-term diuretic use. ( Jefferson, JW; Kalin, NH, 1979)
"Of these, 13 had primary aldosteronism (ALDO), 19 high renin (HRH), 30 low renin (LRH), and 57 normal renin (NRH) essential hypertension."	1.26	Natriuretic response to saline infusion in normotensive and hypertensive man. The role of renin suppression in exaggerated natriuresis. ( Grim, CE; Higgins, JT; Luft, FC; Weinberger, MH; Willis, LR, 1977)
"Patients with post-traumatic "fluid overload" appear to have a combination of hypervolemia, respiratory insufficiency, hypertension, increased cardiac output, decreased extracellular fluid space, and decreased renal perfusion."	1.26	The renal factor in the post-traumatic "fluid overload" syndrome. ( Bradley, VE; Ledgerwood, AM; Lucas, CE; Shier, MR, 1977)
"A case report of preeclampsia in a myasthenic patient is described with recommendations for management."	1.26	Myasthenia gravis and preeclampsia. ( Cohen, BA; Goldstein, PJ; London, RS, 1976)
"Indapamide has a prolonged saluretic action which in combination with the direct vascular effects may well account for its antihypertensive activity."	1.25	Antihypertensive action of indapamide. Comparative studies in several experimental models. ( Kyncl, J; Oheim, K; Seki, T; Solles, A, 1975)

Research

Studies (994)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Change in Diastolic Blood Pressure

Change in Extracellular Water

Timeframe	Studies, this research(%)	All Research%
pre-1990	762 (76.66)	18.7374
1990's	110 (11.07)	18.2507
2000's	44 (4.43)	29.6817
2010's	60 (6.04)	24.3611
2020's	18 (1.81)	2.80

Authors	Studies
Stokker, GE	1
Smith, RL	1
Cragoe, EJ	1
Ludden, CT	1
Russo, HF	1
Sweet, CS	1
Watson, LS	1
Zhu, Y	1
de Jesus, RK	1
Tang, H	1
Walsh, SP	1
Jiang, J	1
Gu, X	1
Teumelsan, N	1
Shahripour, A	1
Pio, B	1
Ding, FX	1
Ha, S	1
Priest, BT	1
Swensen, AM	1
Alonso-Galicia, M	1
Felix, JP	1
Brochu, RM	1
Bailey, T	1
Thomas-Fowlkes, B	1
Zhou, X	1
Pai, LY	1
Hampton, C	1
Hernandez, M	1
Owens, K	1
Ehrhart, J	1
Roy, S	1
Kaczorowski, GJ	1
Yang, L	1
Parmee, ER	1
Sullivan, K	1
Garcia, ML	1
Pasternak, A	1
Cechinel-Zanchett, CC	1
Bolda Mariano, LN	1
Boeing, T	1
da Costa, JC	1
Da Silva, LM	1
Bastos, JK	1
Cechinel-Filho, V	1
de Souza, P	1
Bryniarski, P	1
Nazimek, K	1
Marcinkiewicz, J	1
Tanné, C	1
Pracros, JP	1
Dijoud, F	1
Mure, PY	1
Bordet, F	1
Duncan, A	1
Bacchetta, J	1
Dzhoyashvili, NA	1
Iyer, SR	1
Chen, HH	1
Burnett, JC	1
Ward, JL	1
Guillot, E	1
Domenig, O	1
Ware, WA	1
Yuan, L	1
Mochel, JP	1
Leete, J	1
Wang, C	1
López-Hernández, FJ	1
Layton, AT	1
Nakatsukasa, T	1
Ishizu, T	1
Ouchi, M	1
Murakoshi, N	1
Sato, K	4
Yamamoto, M	1
Kawanishi, K	1
Seo, Y	1
Ieda, M	1
Zhang, Y	1
Song, M	1
Chan, AT	1
Meyerhardt, JA	1
Willett, WC	1
Giovannucci, EL	1
Murasawa, S	1
Kageyama, K	1
Usutani, M	1
Asari, Y	1
Kinoshita, N	1
Nakada, Y	1
Watanuki, Y	1
Takayasu, S	1
Daimon, M	1
Çolak, ST	1
Vızdıklar, C	1
Kaşkal, M	1
Aydın, V	1
Ataç, Ö	1
Akıcı, A	1
Iwamoto, Y	1
Kimura, T	1
Ohnishi, M	1
Kusano, T	1
Takenouchi, H	1
Iwamoto, H	1
Sanada, J	1
Fushimi, Y	1
Katakura, Y	1
Tatsumi, F	1
Shimoda, M	1
Nakanishi, S	1
Kaku, K	1
Mune, T	2
Kaneto, H	1
Bellos, I	1
Pergialiotis, V	1
Papapanagiotou, A	1
Loutradis, D	1
Daskalakis, G	1
Gonçalves, PVB	1
Moreira, FL	1
Benzi, JRL	1
Cavalli, RC	1
Duarte, G	1
Lanchote, VL	1
Andrade-Franzé, GMF	1
Pereira, ED	1
Yosten, GLC	1
Samson, WK	1
Menani, JV	1
De Luca, LA	1
Andrade, CAF	1
Docheva, N	1
Nieman, KM	1
Rana, S	1
Mirihagalle, N	1
Parajuli, P	1
Sundareshan, V	1
Saha, D	1
Shah, A	1
Chua, F	1
Waqar, S	1
Prakash, V	1
Tobian, AAR	1
Bloch, EM	1
Katz, LM	1
Goel, R	1
Ekici, B	1
Yaman, M	1
Küçük, M	1
Dereli, S	1
Yenerçağ, M	1
Yiğit, Z	1
Baş, MM	1
Karavelioğlu, Y	1
Çakmak, HA	1
Kıvrak, T	1
Özkan, H	1
Altın, C	1
Şabanoğlu, C	1
Demirkan, B	1
Ataş, AE	1
Kılıçaslan, F	1
Altay, H	1
Tengiz, İ	1
Fahri Erkan, A	1
Kılıçaslan, B	1
Olgun, FE	1
Durakoğlugil, ME	1
Alhan, A	1
Zoghi, M	1
Kodati, D	1
Yellu, N	1
Spyropoulos, EM	1
Simms, N	1
Clark, C	1
Greco, FA	1
Wang, B	1
Wen, D	1
Li, H	1
Wang-France, J	1
Sansom, SC	1
Shukla, M	1
Ibrahim, MMA	1
Jain, M	1
Jaiswal, S	1
Sharma, A	1
Hanif, K	1
Lal, J	1
James, J	1
Sammour, YM	1
Virata, AR	1
Nordin, TA	1
Dumic, I	1
Ros Forteza, FJ	1
Buttard, M	1
Putot, A	1
d'Athis, P	1
Pioro, L	1
Asgassou, S	1
Putot, S	1
Deïdda, M	1
Laborde, C	1
Dipanda, M	1
Mahmoudi, R	1
Manckoundia, P	1
McCoy, IE	1
Chertow, GM	1
Chang, TI	1
Sato, N	1
Kajimoto, K	1
Keida, T	1
Mizuno, M	1
Minami, Y	1
Yumino, D	1
Asai, K	1
Murai, K	1
Muanakata, R	1
Aokage, T	1
Sakata, Y	1
Mizuno, K	1
Takano, T	1
Ricci, F	1
Ramírez, T	1
Marmorato, R	1
Vega, J	1
Pagán, P	1
López, JE	1
Soto-Salgado, M	1
Cangiano, JL	2
Mori, Y	2
Ogawa, Y	1
Mochizuki, A	2
Nakamura, Y	1
Fujimoto, T	1
Sugita, C	1
Miyazaki, S	5
Tamaki, K	1
Nagayama, T	1
Nagai, Y	1
Inoue, S	1
Chiba, K	1
Nishi, T	1
Tarvasmäki, T	1
Harjola, VP	1
Tolonen, J	1
Siirilä-Waris, K	1
Nieminen, MS	1
Lassus, J	1
De Nicola, L	4
Conte, G	5
Chiodini, P	3
D'Angiò, P	1
Donnarumma, G	1
Minutolo, R	4
Taylor, AT	1
Mulay, SB	1
Greiner, CW	1
Mohr, A	1
Bryant, SC	1
Lingineni, RK	1
Padley, D	1
Hogan, WJ	1
Gastineau, DA	1
Jacob, EK	1
Pruijm, M	1
Hofmann, L	1
Piskunowicz, M	1
Muller, ME	1
Zweiacker, C	1
Bassi, I	1
Vogt, B	1
Stuber, M	1
Burnier, M	1
Hoshino, T	1
Ookawara, S	1
Miyazawa, H	1
Ito, K	2
Ueda, Y	3
Kaku, Y	1
Hirai, K	1
Mori, H	1
Yoshida, I	2
Tabei, K	1
Azizi, M	2
Perdrix, L	1
Bobrie, G	2
Frank, M	2
Chatellier, G	2
Ménard, J	3
Plouin, PF	2
Nakama, C	1
Kamide, K	1
Kawai, T	1
Hongyo, K	1
Ito, N	1
Onishi, M	1
Takeya, Y	1
Yamamoto, K	1
Sugimoto, K	1
Rakugi, H	1
Moreira, MC	1
da Silva, EF	1
Silveira, LL	1
de Paiva, YB	1
de Castro, CH	1
Freiria-Oliveira, AH	1
Rosa, DA	1
Ferreira, PM	1
Xavier, CH	1
Colombari, E	1
Pedrino, GR	1
Kosilov, KV	1
Loparev, SA	1
Ivanovskaya, MA	1
Kosilova, LV	1
Verdalles, U	1
García de Vinuesa, S	1
Goicoechea, M	1
Macías, N	1
Santos, A	1
Perez de Jose, A	1
Verde, E	1
Yuste, C	1
Luño, J	1
Vaidya, A	1
Curhan, GC	2
Paik, JM	1
Kronenberg, H	1
Taylor, EN	1
Musini, VM	1
Rezapour, P	1
Wright, JM	1
Bassett, K	1
Jauca, CD	1
Laster, M	1
Im, D	1
Ahn, A	1
Ho, CH	1
Cursino, T	1
Katz, L	1
Coutinho, I	1
Amorim, M	1
Arias, SC	1
Souza, RA	1
Malheiros, DM	1
Fanelli, C	1
Fujihara, CK	1
Zatz, R	1
Lin, BM	1
Curhan, SG	1
Wang, M	1
Eavey, R	1
Stankovic, KM	1
Torstensson, M	1
Hansen, AH	1
Leth-Møller, K	1
Jørgensen, TS	1
Sahlberg, M	1
Andersson, C	1
Kristensen, KE	1
Ryg, J	1
Weeke, P	1
Torp-Pedersen, C	1
Gislason, G	1
Holm, E	1
Malha, L	1
Mann, SJ	1
Rahman, A	1
Kittikulsuth, W	1
Fujisawa, Y	1
Sufiun, A	1
Rafiq, K	1
Hitomi, H	1
Nakano, D	1
Sohara, E	1
Uchida, S	1
Nishiyama, A	1
Pourzitaki, C	1
Tsaousi, G	1
Manthou, ME	1
Karakiulakis, G	1
Kouvelas, D	1
Papakonstantinou, E	1
Malebranche, R	1
Tabou Moyo, C	1
Morisset, PH	1
Raphael, NA	1
Wilentz, JR	1
Mattu, A	1
Lawner, B	1
Anguita, M	1
Toledano, F	1
León, C	1
Castillo, JC	1
Riazi, S	1
Tiwari, S	1
Sharma, N	1
Rash, A	1
Ecelbarger, CM	1
Gorelik, O	1
Almoznino-Sarafian, D	1
Shteinshnaider, M	1
Alon, I	1
Tzur, I	1
Sokolsky, I	1
Efrati, S	1
Babakin, Z	1
Modai, D	2
Cohen, N	1
Fadel, S	1
Karmali, R	1
Cogan, E	1
Dagan, A	1
Habib, S	1
Gattineni, J	1
Dwarakanath, V	1
Baum, M	1
Sweileh, WM	1
Sawalha, AF	1
Jayousi, HM	1
Zyoud, SH	1
Al-Jabi, SW	1
de Gregorio, C	1
Morabito, G	1
Cerrito, M	1
Dattilo, G	1
Oreto, G	1
Lee, JY	1
Prineas, RJ	1
Eaton, JW	1
Kunt, AT	1
Akgün, S	1
Atalan, N	1
Bitir, N	1
Arsan, S	1
Torchia, D	1
Miteva, M	1
Hu, S	1
Cohen, C	1
Romanelli, P	1
Rahman, M	1
Kim, SJ	1
Kim, JS	1
Kim, SZ	1
Lee, YU	1
Kang, HS	1
Zamboli, P	3
Crivaro, M	1
Tassinario, S	1
Bellizzi, V	1
Kujal, P	1
Chábová, VČ	1
Vernerová, Z	1
Walkowska, A	1
Kompanowska-Jezierska, E	1
Sadowski, J	1
Vaňourková, Z	1
Husková, Z	1
Opočenský, M	1
Skaroupková, P	1
Schejbalová, S	1
Kramer, HJ	1
Rakušan, D	1
Malý, J	1
Netuka, I	1
Vaněčková, I	1
Kopkan, L	1
Cervenka, L	1
Kuriyama, S	1
Otsuka, Y	5
Ueda, H	1
Sugano, N	1
Yoshizawa, T	1
Yamada, T	1
Hosoya, T	1
Handler, J	1
Holzer-Richling, N	1
Holzer, M	1
Herkner, H	1
Riedmüller, E	1
Havel, C	1
Kaff, A	1
Malzer, R	1
Schreiber, W	1
Manrique Franco, K	1
López-Mezquita Torres, E	1
Sánchez García, L	1
Aragón Valera, C	1
Sanchez-Vilar Burdiel, O	1
Rubino, AS	1
Serraino, GF	1
Mariscalco, G	1
Marsico, R	1
Sala, A	1
Renzulli, A	1
Haque, MZ	1
Ares, GR	1
Caceres, PS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial[NCT02163655]	Phase 4	120 participants (Actual)	Interventional	2014-03-31	Completed
Prospective, Randomised, Open, Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure[NCT00409942]	Phase 4	142 participants (Actual)	Interventional	2007-03-31	Completed
The Biological Characteristics of Adipose Tissue-derived Mesenchymal Stem Cells and Its Role in the Treatment of Chronic Renal Failure[NCT03321942]		100 participants (Anticipated)	Interventional	2017-01-01	Recruiting
Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933]	Phase 2	34 participants (Actual)	Interventional	2019-06-18	Completed
Lasix for the Prevention of De Novo Postpartum Hypertension: A Randomized Controlled Trial (LAPP Trial)[NCT04752475]	Phase 3	82 participants (Actual)	Interventional	2021-10-20	Completed
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide: A Randomized Controlled Trial[NCT04343235]	Phase 4	13 participants (Actual)	Interventional	2020-05-01	Terminated (stopped due to Challenges with enrollment; primary investigator left the institution)
A Randomized Control Trial of Furosemide or Placebo With Usual Antihypertensives in the Antepartum Management of Severe Hypertension With Wide Pulse Pressure[NCT04615624]	Phase 3	65 participants (Actual)	Interventional	2021-01-04	Completed
Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet on Ventriculovascular Function in Heart Failure With Preserved Systolic Function[NCT00939640]		14 participants (Actual)	Interventional	2009-07-31	Completed
The Function of Dopaminergic and Noradrenergic Systems in Salt-Sensitive Hypertension: The Effects of Changes in Sodium Intake[NCT00001176]		110 participants	Observational	1981-05-31	Completed
[NCT00005268]		0 participants	Observational	1995-09-30	Completed
Once Versus Twice Daily Electrolyte Monitoring in CHF; a Study Monitoring Electrolytes in Congestive Heart Failure Patients Being Actively Diuresed in Hospital[NCT02497742]		96 participants (Actual)	Interventional	2015-10-31	Completed
Salt-Sensitivity and Immunity Cell Activation[NCT03753204]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2021-09-01	Recruiting
Bioequivalence Study of Furosemide in Indonesian Healthy Volunteers[NCT04982874]		24 participants (Actual)	Interventional	2019-12-13	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	mmHg (Mean)
Placebo	-3.4
Treatment Grup	-13.5

Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28

Change in Extracellular Water / Total Body Water Ratio

Intervention	litres (Mean)
Placebo	-0.15
Treatment Grup	2.55

Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28

Change in Mean Arterial Pressure

Intervention	percentage of ECW/TBW (Mean)
Placebo	-0.24
Treatment Grup	-2.92

decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28

Change in Systolic Blood Pressure

Change in the Fractional Excretion of Sodium

Intervention	mmHg (Mean)
Placebo	-5.4
Treatment Grup	-18.1

Intervention	mmHg (Mean)
Placebo	-10
Treatment Grup	-26.1

Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28

Change in Total Body Water

Intervention	percentage of sodium excreted (Mean)
Placebo	-0.348
Treatment Grup	0.598

Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28

Mean Arterial Blood Pressure (MAP)

Intervention	litres (Mean)
Placebo	-0.075
Treatment Grup	-4.36

Difference in MAP averaged over the 24 hours prior to discharge or the 24 hours prior to antihypertensive therapy initiation (whichever occurs first) (NCT04752475)
Timeframe: 24 hours prior to discharge through discharge, up to 7 days

Breastfeeding Status

Intervention	mmHg (Mean)
Lasix (Furosemide)	88.9
Placebo	86.8

breastfeeding continuation after discharge (NCT04343235)
Timeframe: at 1 week postpartum visit

Change of Dose for Antihypertensive Therapy

Intervention	Participants (Count of Participants)
Labetalol + Furosemide	1
Labetalol Only	3

number of patients who require a change in the dose of labetalol to control BP (NCT04343235)
Timeframe: Change in dose of hypertensive therapy from randomization until hospital discharge (up to 7 days)

Hospital Length of Stay

Intervention	Participants (Count of Participants)
Labetalol + Furosemide	3
Labetalol Only	0

days in hospital after delivery (NCT04343235)
Timeframe: Number of days of hospital stay from randomization to discharge

Hospital Readmission

Intervention	days (Mean)
Labetalol + Furosemide	3.5
Labetalol Only	4.3

readmission for hypertension management (NCT04343235)
Timeframe: up to 14 days after discharge

Change of Gestational Hypertensive Disorder Symptoms (Diastolic BP)

Intervention	Participants (Count of Participants)
Labetalol + Furosemide	1
Labetalol Only	2

average diastolic blood pressure reading on Day 0, Day 1, and Day 2 (NCT04343235)
Timeframe: Average diastolic blood pressure on Day 0, Day 1, and Day 2

Change of Gestational Hypertensive Disorder Symptoms (Mean Arterial Pressure)

Intervention	mm of mercury (Mean)
	Day 0	Day 1	Day 2
Labetalol + Furosemide	84.1	81.8	78.8
Labetalol Only	80.1	80.7	75.5

average mean arterial pressure reading on Day 0, Day 1, and Day 2 (NCT04343235)
Timeframe: Average mean arterial pressure on Day 0, Day 1, and Day 2

Change of Gestational Hypertensive Disorder Symptoms (Systolic BP)

Intervention	mm of mercury (Mean)
	Day 0	Day 1	Day 2
Labetalol + Furosemide	102.4	99.5	98.0
Labetalol Only	100.0	100.1	96.0

average systolic blood pressure reading on Day 0, Day 1, and Day 2 (NCT04343235)
Timeframe: Average systolic blood pressure for Day 0, Day 1, and Day 2

Aortic Augmentation Index

Intervention	mm of mercury (Mean)
	Day 0	Day 1	Day 2
Labetalol + Furosemide	138.4	134.9	135.2
Labetalol Only	138.1	138.2	136.7

Aortic augmentation index is the ratio of the augmentation pressure to the central pulse pressure, expressed as a percentage. Both parameters are obtained via mathematical transformation of the radial pulse wave. The augmentation pressure represents the contribution of reflected waves to the pulse pressure. The central pulse pressure is the ratio between maximum aortic systolic pressure and minimum aortic diastolic pressure. A higher aortic augmentation index and central pulse pressure reflect increased arterial stiffness. Increased arterial stiffness is associated with an increased long-term risk of cardiovascular disease. (NCT00939640)
Timeframe: Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation

Brachial Artery Flow-mediated Dilation (FMD)

Intervention	percentage (Mean)
Pre-Dietary Intervention	29
Post-dietary Intervention	28

(NCT00939640)
Timeframe: Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation

Carotid-femoral Pulse Wave Velocity

Intervention	% dilation (Mean)
Pre-dietary Intervention	5
Post-dietary Intervention	8

(NCT00939640)
Timeframe: Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation

Diurnal Variation in Ambulatory Blood Pressure

Intervention	m/s (Mean)
Pre-Dietary Intervention	12.4
Post-Dietary Intervention	11.0

Number of participants with non-dipping of nocturnal blood pressure - nighttime-to-daytime systolic BP ratio of >= 0.9 (NCT00939640)
Timeframe: Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation

Mean 24-hour Systolic Blood Pressure

Intervention	Participants (Count of Participants)
Pre-Dietary Intervention	10
Post-dietary Intervention	7

Change in 24-hour systolic blood pressure (NCT00939640)
Timeframe: Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation

Six Minute Walk Test Distance

Intervention	mm Hg (Mean)
Pre-dietary Intervention	130
Post-dietary Intervention	123

(NCT00939640)
Timeframe: Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation

Urinary 8-isoprostanes

Intervention	meters (Mean)
Pre-Dietary Intervention	313
Post-Dietary Intervention	337

(NCT00939640)
Timeframe: Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation

Ventricular Diastolic Function

Intervention	mmol F2-iso/mmol Cr (Mean)
Pre-Dietary Intervention	70
Post-Dietary Intervention	48

Lateral mitral annulus E/e' ratio (NCT00939640)
Timeframe: Prior to and following 21 days of dietary intervention, i.e. day 1 and day 22 of participation

Geometric Mean Ratio of Area Under Curve

Intervention	ratio (Mean)
Pre-Dietary Intervention	12
Post-Dietary Intervention	11

The ratio between test drug and reference drug (NCT04982874)
Timeframe: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration

Geometric Mean Ratio of Maximum Concentration

Intervention	percentage (Geometric Mean)
Furosemide 40 mg Tablet	101.79

The ratio between test drug and reference drug (NCT04982874)
Timeframe: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration

Pharmacokinetics Parameter

Intervention	percentage (Geometric Mean)
Furosemide 40 mg Tablet	104.51

Area Under Curve from 0 to 24 hours (NCT04982874)
Timeframe: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration

Pharmacokinetics Parameter

Intervention	ng*h/mL (Mean)
Furosemide 40 mg Tablet	4938.79
Lasix® 40 mg Tablet	4921.94

Maximum plasma concentration (NCT04982874)
Timeframe: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration

Article	Year
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. American journal of obstetrics and gynecology, 2020, Volume: 223, Issue:4 Topics: Abruptio Placentae; Amlodipine; Antihypertensive Agents; Atenolol; Cesarean Section; Chronic Disease	2020
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature. The American journal of case reports, 2018, Feb-14, Volume: 19 Topics: Biopsy, Needle; Combined Modality Therapy; Critical Care; Critical Illness; Diuretics; Drug Hypersen	2018
Radionuclides in nephrourology, Part 2: pitfalls and diagnostic applications. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:5 Topics: Aged; Decision Support Techniques; Diuresis; False Positive Reactions; Furosemide; Humans; Hypertens	2014
Blood pressure-lowering efficacy of loop diuretics for primary hypertension. The Cochrane database of systematic reviews, 2015, May-22, Issue:5 Topics: Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Furosemide; Humans; Hyper	2015
Loop Diuretics in the Treatment of Hypertension. Current hypertension reports, 2016, Volume: 18, Issue:4 Topics: Antihypertensive Agents; Blood Pressure; Diuretics; Furosemide; Humans; Hypertension; Thiazides	2016
Prehospital management of congestive heart failure. Heart failure clinics, 2009, Volume: 5, Issue:1 Topics: Advanced Cardiac Life Support; Angiotensin-Converting Enzyme Inhibitors; Bronchodilator Agents; Clin	2009
[Hypertension, hypertensive heart disease and heart failure. Role of loop diuretics]. Medicina clinica, 2008, Nov-15, Volume: 131, Issue:17 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive	2008
Papuloerythroderma 2009: two new cases and systematic review of the worldwide literature 25 years after its identification by Ofuji et al. Dermatology (Basel, Switzerland), 2010, Volume: 220, Issue:4 Topics: Aged, 80 and over; Female; Furosemide; Humans; Hydroxyzine; Hypercholesterolemia; Hypertension; Male	2010
[Modes of clinical presentation of glomerular diseases]. La Revue du praticien, 2003, Nov-30, Volume: 53, Issue:18 Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bed Rest; Biopsy; Child; D	2003
Management of hypertension in chronic kidney disease. Current hypertension reports, 2006, Volume: 8, Issue:6 Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Dise	2006
[Screening tests and diagnostic examinations of hypertensives for primary aldosteronism]. Rinsho byori. The Japanese journal of clinical pathology, 2006, Volume: 54, Issue:11 Topics: Adrenal Cortex Function Tests; Adrenalectomy; Adrenocorticotropic Hormone; Aldosterone; Antihyperten	2006
The kinins and prostaglandins in hypertension. Clinics in endocrinology and metabolism, 1981, Volume: 10, Issue:3 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Water; Dinoprost; Female; Furos	1981
Practical therapeutics: the role of diuretics in current medicine. East African medical journal, 1983, Volume: 60, Issue:9 Topics: Benzothiadiazines; Diuretics; Furosemide; Humans; Hypertension; Hypokalemia; Potassium; Sodium Chlor	1983
Anti-hypertensive drugs in the pregnant patient. Obstetrical & gynecological survey, 1980, Volume: 35, Issue:4 Topics: Antihypertensive Agents; Chronic Disease; Clonidine; Diazoxide; Diuretics; Female; Fetus; Furosemide	1980
Sodium and hypertension. A review of the role of sodium in pathogenesis and the action of diuretic drugs. Pharmacology & therapeutics, 1980, Volume: 9, Issue:3 Topics: Age Factors; Aldosterone; Amiloride; Benzothiadiazines; Diuretics; Furosemide; Humans; Hypertension;	1980
Possible significance of renal prostaglandins in essential hypertension. Clinical and experimental hypertension, 1980, Volume: 2, Issue:3-4 Topics: Animals; Blood Flow Velocity; Child; Female; Furosemide; Glomerular Filtration Rate; Humans; Hyperte	1980
Renal prostaglandins, kidney function and essential hypertension. Contributions to nephrology, 1980, Volume: 23 Topics: Animals; Furosemide; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Prostaglandins; Rabbi	1980
[Treatment of arterial hypertension in elderly patients]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 1981, Aug-15, Volume: 34, Issue:16 Topics: Age Factors; Aged; Antihypertensive Agents; Chlorpromazine; Diazoxide; Dihydralazine; Drug Therapy,	1981
Bullous pemphigoid after treatment with furosemide. Cutis, 1996, Volume: 58, Issue:5 Topics: Aged; Fluorescent Antibody Technique, Direct; Furosemide; Humans; Hypertension; Male; Pemphigoid, Bu	1996
Diuretics and the therapy of hypertension. The American journal of the medical sciences, 2000, Volume: 319, Issue:1 Topics: Antihypertensive Agents; Blood Pressure; Chlorothiazide; Diuretics; Edema; Furosemide; Guidelines as	2000
[Management of high blood pressure using beta-sympatholytics. Review]. Fortschritte der Medizin, 1976, Nov-11, Volume: 94, Issue:32 Topics: Adrenergic beta-Antagonists; Clonidine; Furosemide; Guanethidine; Humans; Hydralazine; Hypertension;	1976
[Current treatment of arterial hypertension]. Zeitschrift fur arztliche Fortbildung, 1977, Apr-15, Volume: 71, Issue:8 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Clonidine; Dihydralazine; F	1977
[Pharmacologic functional examination in arterial hypertension]. Der Internist, 1977, Volume: 18, Issue:11 Topics: Adrenergic beta-Antagonists; Angiotensin II; Blood Pressure; Diagnosis, Differential; Diuretics; Fer	1977
Preventing, detecting and managing adverse reactions of antihypertensive agents in the ambulant patient with essential hypertension. American journal of hospital pharmacy, 1977, Volume: 34, Issue:5 Topics: Antihypertensive Agents; Benzothiadiazines; Clonidine; Diuretics; Drug Interactions; Ethacrynic Acid	1977
Neural control of renin release. Clinical science and molecular medicine. Supplement, 1975, Volume: 2 Topics: Animals; Cats; Dogs; Electric Stimulation; Ethacrynic Acid; Furosemide; Humans; Hypertension; Hypoth	1975
Aldosterone and renin in essential hypertension. Canadian Medical Association journal, 1975, Sep-06, Volume: 113, Issue:5 Topics: 18-Hydroxydesoxycorticosterone; Adult; Age Factors; Aldosterone; Angiotensin II; Clinical Trials as	1975
Your patient and angina. RDH, 1991, Volume: 11, Issue:5 Topics: Angina Pectoris; Clonidine; Drug Interactions; Female; Flurazepam; Furosemide; Humans; Hypertension;	1991
Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clinical pharmacokinetics, 1990, Volume: 18, Issue:5 Topics: Acute Kidney Injury; Furosemide; Heart Failure; Humans; Hypertension; Liver Diseases	1990
Effects of atrial natriuretic factor on renal function and cyclic GMP production. Federation proceedings, 1986, Volume: 45, Issue:7 Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Calcium; Cyclic GMP; Enzyme Activation; Furosemi	1986
Essential hypertension: new insights and controversies in treatment with diuretics. Southern medical journal, 1986, Volume: 79, Issue:8 Topics: Amiloride; Antihypertensive Agents; Blood Pressure; Coronary Disease; Diuretics; Dose-Response Relat	1986
[Treatment of the hypertensive crisis]. Schweizerische medizinische Wochenschrift, 1973, Nov-24, Volume: 103, Issue:47 Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Diaz	1973
[Principles of combining hypotensive agents (review of the literature)]. Vrachebnoe delo, 1974, Volume: 4 Topics: Antihypertensive Agents; Blood Pressure; Blood Volume; Cardiac Glycosides; Dose-Response Relationshi	1974
Diuretic therapy. The British journal of dermatology, 1972, Volume: 86, Issue:5 Topics: Bendroflumethiazide; Diuretics; Edema; Furosemide; Humans; Hypertension; Skin Diseases; Thiadiazines	1972
The clinical use of diuretics. 2. The New England journal of medicine, 1973, Mar-01, Volume: 288, Issue:9 Topics: Acute Kidney Injury; Diabetes Insipidus; Diuretics; Ethacrynic Acid; Furosemide; Humans; Hypertensio	1973
Significance of hypokalaemia due to diuretics. The Netherlands journal of medicine, 1973, Volume: 16, Issue:1 Topics: Amiloride; Arrhythmias, Cardiac; Chlorothiazide; Diuretics; Ethacrynic Acid; Extracellular Space; Fu	1973
Use of diuretics in nonedematous states. Texas medicine, 1973, Volume: 69, Issue:7 Topics: Absorption; Bromides; Calcium; Cystinuria; Diuretics; Fanconi Syndrome; Furosemide; Humans; Hyperten	1973
[What is assured in drug therapy of cerebrovascular circulation disorders?]. Medizinische Klinik, 1973, Jul-20, Volume: 68, Issue:29 Topics: Brain Edema; Carbon Dioxide; Cerebrovascular Circulation; Cerebrovascular Disorders; Dextrans; Digit	1973
Correlation of pathophysiology and pharmacotherapy in primary hypertension. The American journal of cardiology, 1973, Sep-20, Volume: 32, Issue:4 Topics: Blood Pressure; Cardiac Output; Cardiac Volume; Diuretics; Furosemide; Guanethidine; Heart Failure;	1973
Lymphoceles associated with renal transplantation: report of fifteen cases and review of the literature. Proceedings of the Clinical Dialysis and Transplant Forum, 1973, Volume: 3 Topics: Anuria; Cysts; Diagnosis, Differential; Drainage; Fever; Furosemide; Graft Rejection; Humans; Hypert	1973
Clinical pharmacology of furosemide and ethacrynic acid. The American journal of cardiology, 1968, Volume: 22, Issue:2 Topics: Anuria; Diabetes Insipidus; Edema; Ethacrynic Acid; Furosemide; Heart Failure; Hemodynamics; Humans;	1968
Recent advances in the medical and surgical treatment of hypertension. The Medical clinics of North America, 1968, Volume: 52, Issue:5 Topics: Adrenocortical Hyperfunction; Antihypertensive Agents; Diet, Sodium-Restricted; Diuretics; Ethacryni	1968
[Hypertension--diuretics as antihypertensive agents]. Nihon rinsho. Japanese journal of clinical medicine, 1970, Volume: 28, Issue:4 Topics: Aged; Antihypertensive Agents; Arthritis; Benzothiadiazines; Blood Pressure; Chlorothiazide; Chlorth	1970
The physiology of intravenous urography. The Scientific basis of medicine annual reviews, 1971 Topics: Angiography; Biological Transport, Active; Contrast Media; Dehydration; Diuresis; Furosemide; Glomer	1971
[When and which diuretics? General and specific indications for diuretic therapy]. Der Internist, 1971, Volume: 12 Topics: Acid-Base Equilibrium; Brain Edema; Diuresis; Diuretics; Edema; Ethacrynic Acid; Furosemide; Humans;	1971
[Side effects of antihypertensive therapy]. Zeitschrift fur arztliche Fortbildung, 1970, Oct-01, Volume: 64, Issue:19 Topics: Acetazolamide; Antihypertensive Agents; Blood Pressure; Furosemide; Humans; Hydralazine; Hydrochloro	1970
Diuretics. II. Clinical considerations. Drugs, 1971, Volume: 1, Issue:2 Topics: Administration, Oral; Aminophylline; Ascites; Calcium; Carbohydrate Metabolism; Carbonic Anhydrase I	1971
Aldosterone and electrolyte balance in human hypertension. Journal of the Royal College of Physicians of London, 1970, Volume: 5, Issue:1 Topics: Adrenocortical Hyperfunction; Aldosterone; Animals; Corticosterone; Furosemide; Humans; Hyperaldoste	1970

Article	Year
Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:4 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Diabetes Compl	2013
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. Journal of hypertension, 2014, Volume: 32, Issue:10 Topics: Adolescent; Adult; Aged; Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers	2014
Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin. Current aging science, 2014, Volume: 7, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method;	2014
Diuretics vs. placebo for postpartum blood pressure control in preeclampsia (DIUPRE): a randomized clinical trial. Reproductive health, 2015, Aug-05, Volume: 12 Topics: Blood Pressure; Diuretics; Eclampsia; Female; Furosemide; Humans; Hypertension; Length of Stay; Magn	2015
Furosemide infusion prevents the requirement of renal replacement therapy after cardiac surgery. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2009, Volume: 9, Issue:6 Topics: Adult; Aged; Coronary Artery Bypass; Creatinine; Diabetes Mellitus; Diuresis; Diuretics; Female; Fur	2009
Myocardial calcification and hypertension following chronic renal failure and ameliorative effects of furosemide and captopril. Cardiology, 2010, Volume: 116, Issue:3 Topics: Analysis of Variance; Animals; Antihypertensive Agents; Calcinosis; Captopril; Cardiomyopathies; Dis	2010
Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:5 Topics: Aged; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Creatinine; Echocardiography; F	2011
Randomized placebo controlled trial of furosemide on subjective perception of dyspnoea in patients with pulmonary oedema because of hypertensive crisis. European journal of clinical investigation, 2011, Volume: 41, Issue:6 Topics: Aged; Aged, 80 and over; Diuretics; Double-Blind Method; Dyspnea; Female; Furosemide; Humans; Hypert	2011
Leukocyte depletion during extracorporeal circulation allows better organ protection but does not change hospital outcomes. The Annals of thoracic surgery, 2011, Volume: 91, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Amidohydrolases; Atrial Fibrillation; Comorbidity; Coronary Artery B	2011
Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clinical therapeutics, 2011, Volume: 33, Issue:9 Topics: Aged; Biomarkers; Chronic Disease; Delayed-Action Preparations; Diuretics; Endpoint Determination; F	2011
A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. Journal of clinical hypertension (Greenwich, Conn.), 2012, Volume: 14, Issue:1 Topics: Aged; Anthropology; Biological Availability; Blood Pressure; Chronic Disease; Diet Records; Diuretic	2012
Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. Journal of hypertension, 2012, Volume: 30, Issue:8 Topics: Adolescent; Adult; Aged; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Biological Transport;	2012
Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial. Clinical and experimental hypertension (New York, N.Y. : 1993), 2013, Volume: 35, Issue:5 Topics: Aged; Aldosterone; Amiloride; Angiotensin II; Aquaporin 2; Blood Pressure; Cross-Over Studies; Diure	2013
Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic Acid in human salt-sensitive versus salt-resistant hypertension. Circulation, 2003, Feb-04, Volume: 107, Issue:4 Topics: Adult; Blood Pressure; Creatinine; Diet, Sodium-Restricted; Female; Furosemide; Humans; Hydroxyeicos	2003
A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:2 Topics: Adult; Aged; Chlorides; Cross-Over Studies; Diuretics; Double-Blind Method; Furosemide; Humans; Hydr	2005
Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology, 2005, Volume: 105, Issue:1 Topics: Adult; Antihypertensive Agents; Diuresis; Diuretics; Female; Furosemide; Humans; Hypertension; Postp	2005
Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology, 2005, Volume: 105, Issue:1 Topics: Adult; Antihypertensive Agents; Diuresis; Diuretics; Female; Furosemide; Humans; Hypertension; Postp	2005
Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology, 2005, Volume: 105, Issue:1 Topics: Adult; Antihypertensive Agents; Diuresis; Diuretics; Female; Furosemide; Humans; Hypertension; Postp	2005
Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology, 2005, Volume: 105, Issue:1 Topics: Adult; Antihypertensive Agents; Diuresis; Diuretics; Female; Furosemide; Humans; Hypertension; Postp	2005
Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology, 2005, Volume: 105, Issue:1 Topics: Adult; Antihypertensive Agents; Diuresis; Diuretics; Female; Furosemide; Humans; Hypertension; Postp	2005
Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology, 2005, Volume: 105, Issue:1 Topics: Adult; Antihypertensive Agents; Diuresis; Diuretics; Female; Furosemide; Humans; Hypertension; Postp	2005
Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology, 2005, Volume: 105, Issue:1 Topics: Adult; Antihypertensive Agents; Diuresis; Diuretics; Female; Furosemide; Humans; Hypertension; Postp	2005
Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology, 2005, Volume: 105, Issue:1 Topics: Adult; Antihypertensive Agents; Diuresis; Diuretics; Female; Furosemide; Humans; Hypertension; Postp	2005
Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstetrics and gynecology, 2005, Volume: 105, Issue:1 Topics: Adult; Antihypertensive Agents; Diuresis; Diuretics; Female; Furosemide; Humans; Hypertension; Postp	2005
The effect of diuretics on red blood cell microrheological parameters in female hypertensive patients. Clinical hemorheology and microcirculation, 2005, Volume: 33, Issue:2 Topics: Blood Viscosity; Diuretics; Erythrocyte Aggregation; Erythrocytes; Female; Furosemide; Hematologic T	2005
[The effects of furosemide on beta-blocker-induced hemodynamic changes in patients with hypertension (author's transl)]. Zeitschrift fur Kardiologie, 1980, Volume: 69, Issue:11 Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Cardiac Output; Furosemide; Hemodynamics; Humans	1980
Assessment of the antihypertensive effect of a retard preparation of furosemide (Lasix retard) in monotherapy of mild hypertension. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1981, Volume: 64, Issue:12 Topics: Aged; Blood Glucose; Blood Pressure; Delayed-Action Preparations; Female; Furosemide; Humans; Hypert	1981
Penbutolol in hypertension, alone and in combination with furosemide. A long-term multicentre study. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1983, Jan-29, Volume: 63, Issue:5 Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Furosemide	1983
Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. The American journal of medicine, 1983, Volume: 74, Issue:6 Topics: Blood Pressure; Clinical Trials as Topic; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Mal	1983
Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial. The American journal of medicine, 1983, Oct-17, Volume: 75, Issue:4A Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinatio	1983
A comparison of a combination of penbutolol and frusemide with the two compounds individually in the treatment of hypertension. British journal of clinical pharmacology, 1983, Volume: 16, Issue:5 Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Furosemide; Humans	1983
[Antihypertensive therapy in chronic kidney failure. Comparison of pharmacologic effect of metolazone and furosemide]. Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1983, Nov-08, Volume: 72, Issue:45 Topics: Adult; Aged; Clinical Trials as Topic; Diuretics; Double-Blind Method; Female; Furosemide; Humans; H	1983
Long-acting and short-acting diuretics in the treatment of hypertension. Pharmatherapeutica, 1983, Volume: 3, Issue:7 Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Female; Furosemide; Humans; Hyperte	1983
Cerebral symptoms and blood pressure during parenteral administration of chlorpromazine, dihydralazine and diazoxide. Danish multicenter study on acute severe hypertension. Acta medica Scandinavica. Supplementum, 1983, Volume: 678 Topics: Blood Pressure; Brain Diseases; Brain Ischemia; Chlorpromazine; Clinical Trials as Topic; Diazoxide;	1983
[Captopril in hypertensive crises]. Arquivos brasileiros de cardiologia, 1984, Volume: 42, Issue:1 Topics: Benzodiazepines; Blood Pressure; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Fem	1984
Pharmacodynamics and kinetics of etozolin/ozolinone in hypertensive patients with normal and impaired kidney function. European journal of clinical pharmacology, 1984, Volume: 26, Issue:6 Topics: Adult; Antihypertensive Agents; Diuretics; Female; Furosemide; Humans; Hypertension; Kidney Failure,	1984
[Comparative evaluation of a diuretic combination versus single components]. La Clinica terapeutica, 1984, Nov-30, Volume: 111, Issue:4 Topics: Clinical Trials as Topic; Drug Therapy, Combination; Edema; Furosemide; Humans; Hypertension; Potass	1984
[Efficacy and safety of captopril in low doses, alone or combined with diuretics, in the treatment of mild or moderate arterial hypertension]. Arquivos brasileiros de cardiologia, 1984, Volume: 43, Issue:2 Topics: Aged; Blood Pressure; Captopril; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Fem	1984
Sodium sensitivity in essential hypertension: role of the renin-angiotensin-aldosterone system and predictive value of an intravenous frusemide test. Journal of hypertension, 1984, Volume: 2, Issue:1 Topics: Adult; Aldosterone; Blood Pressure; Body Weight; Diet; Female; Furosemide; Humans; Hypertension; Mal	1984
Responses to furosemide in normotensive and hypertensive subjects. Clinical pharmacology and therapeutics, 1983, Volume: 34, Issue:5 Topics: 6-Ketoprostaglandin F1 alpha; Adult; Female; Furosemide; Humans; Hypertension; Male; Middle Aged; So	1983
[3-step plan for the treatment of hypertension]. Die Medizinische Welt, 1982, Nov-19, Volume: 33, Issue:46 Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; F	1982
[Hypertensive crisis. Treatment with captopril after failure with a diuretic. Multicenter study]. Arquivos brasileiros de cardiologia, 1982, Volume: 38, Issue:5 Topics: Administration, Oral; Adult; Blood Pressure; Captopril; Clinical Trials as Topic; Diazepam; Drug The	1982
[Guanfacine in primary arterial hypertension: a long-term open clinical study]. Revista medica de Chile, 1982, Volume: 110, Issue:12 Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combinatio	1982
Treatment of benign essential hypertension with frusemide in different doses. Pharmatherapeutica, 1980, Volume: 2, Issue:5 Topics: Adult; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Meth	1980
Urinary zinc excretion during treatment with different diuretics. Acta medica Scandinavica, 1980, Volume: 208, Issue:3 Topics: Adult; Aged; Bendroflumethiazide; Bumetanide; Chlorthalidone; Clinical Trials as Topic; Diuretics; F	1980
[Clinical trial of the activity and therapeutic effectiveness of 3 drugs with diuretic and antihypertensive action]. Minerva medica, 1981, Jan-21, Volume: 72, Issue:2 Topics: Aged; Antihypertensive Agents; Blood; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Diur	1981
The patient with mild to moderate essential hypertension: peripheral renin activity and a comparative drug study. The Journal of the Indiana State Medical Association, 1981, Volume: 74, Issue:7 Topics: Adult; Age Factors; Blood Pressure; Chlorothiazide; Clinical Trials as Topic; Double-Blind Method; D	1981
[Treatment of acute, severe hypertension assessed in a multicentre study. The effects of rest and furosemide and a randomized clinical trial of chlorpromazine, dihydralazine and diazoxide]. Ugeskrift for laeger, 1981, Jun-01, Volume: 143, Issue:23 Topics: Adult; Aged; Bed Rest; Chlorpromazine; Clinical Trials as Topic; Diazoxide; Female; Furosemide; Huma	1981
[Effect of propranolol on diuretic activity of furosemide hypertensive patients (author's transl)]. Nephrologie, 1981, Volume: 2, Issue:4 Topics: Aldosterone; Diuresis; Drug Synergism; Female; Furosemide; Humans; Hypertension; Male; Osmolar Conce	1981
Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. The American journal of medicine, 1982, Volume: 72, Issue:6 Topics: Adult; Body Weight; Clinical Trials as Topic; Diuretics; Drug Combinations; Female; Furosemide; Huma	1982
Experience with once-daily and twice-daily slow-release frusemide in hypertension. The Journal of international medical research, 1982, Volume: 10, Issue:4 Topics: Adult; Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind M	1982
Moderate sodium restriction and various diuretics in the treatment of hypertension. Archives of internal medicine, 1981, Volume: 141, Issue:8 Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diet, Sodium-Restricted; Diuretics;	1981
Controlled comparison of the effects of furosemide and hydrochlorothiazide added to propranolol in the treatment of hypertension. American heart journal, 1981, Volume: 102, Issue:4 Topics: Adult; Aged; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Furosemide; Heart Rate;	1981
Emergency treatment of severe hypertension evaluated in a randomized study. Effect of rest and furosemide and a randomized evaluation of chlorpromazine, dihydralazine and diazoxide. Danish Multicenter Study. Acta medica Scandinavica, 1980, Volume: 208, Issue:6 Topics: Adult; Aged; Chlorpromazine; Denmark; Diazoxide; Dihydralazine; Drug Administration Schedule; Female	1980
Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. Diabetes care, 1995, Volume: 18, Issue:7 Topics: Albuminuria; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Blood P	1995
Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1995, Volume: 26, Issue:1 Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Bendroflumethiazide; Blood Pressure; C	1995
Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. International journal of cardiology, 1995, Volume: 49, Issue:3 Topics: Adult; Aged; Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Chronic Disease; Coronary Disease; Cro	1995
Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. Journal of human hypertension, 1995, Volume: 9, Issue:2 Topics: Aged; Analysis of Variance; Body Weight; Cross-Over Studies; Double-Blind Method; Female; Furosemide	1995
The renin angiotensin aldosterone system and frusemide response in congestive heart failure. British journal of clinical pharmacology, 1995, Volume: 39, Issue:1 Topics: Administration, Oral; Aged; Aldosterone; Captopril; Cross-Over Studies; Drug Therapy, Combination; F	1995
Recognition of markers of response to potassium-canrenoate in essential hypertension. Steroids, 1995, Volume: 60, Issue:1 Topics: Adult; Aged; Biomarkers; Canrenoic Acid; Cross-Over Studies; Female; Furosemide; Humans; Hypertensio	1995
Low plasma 19-hydroxyandrostenedione levels in patients with aldosterone-producing adenoma. Endocrine journal, 1993, Volume: 40, Issue:1 Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aged; Aldosterone; Androstenedione; Blood Pressure; Dexamet	1993
Does furosemide prevent hypertension during perioperative splenectomy in thalassemic children? Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1995, Volume: 78, Issue:10 Topics: Chi-Square Distribution; Child; Furosemide; Hemodynamics; Humans; Hypertension; Injections, Intraven	1995
Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. European journal of clinical pharmacology, 1996, Volume: 51, Issue:1 Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent	1996
The kidney and hypertension. Hypertension research : official journal of the Japanese Society of Hypertension, 1997, Volume: 20, Issue:2 Topics: Animals; Blood Pressure; Calcium Channel Blockers; Creatinine; Furosemide; Hemodynamics; Humans; Hyp	1997
Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency. Clinical nephrology, 1997, Volume: 48, Issue:4 Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydro	1997
Fluctuations in blood lipid levels during furosemide therapy: a randomized, double-blind, placebo-controlled crossover study. Archives of internal medicine, 1998, Jul-13, Volume: 158, Issue:13 Topics: Aged; Apolipoproteins; Cholesterol; Chronic Disease; Cross-Over Studies; Diuretics; Double-Blind Met	1998
A randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: the bumetanide and furosemide on lipid profile (BUFUL) clinical study report. Journal of clinical pharmacology, 1998, Volume: 38, Issue:7 Topics: Adult; Aged; Antihypertensive Agents; Bumetanide; Cross-Over Studies; Diuretics; Double-Blind Method	1998
Hemodynamic responses to captopril during splenectomy in thalassemic children. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1999, Volume: 82, Issue:7 Topics: Administration, Oral; Analysis of Variance; Antihypertensive Agents; beta-Thalassemia; Captopril; Ch	1999
Use of Valsalva's maneuver to detect early recurrence of congestive heart failure in a randomized trial of furosemide withdrawal in older patients. Journal of the American Geriatrics Society, 1999, Volume: 47, Issue:11 Topics: Aged; Blood Pressure; Cardiac Output; Confidence Intervals; Diuretics; Edema; Follow-Up Studies; Fur	1999
Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:9 Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aldosterone; Area Under Curve; Case-Control Studies; Diuret	2001
Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker. International journal of clinical pharmacology and therapeutics, 2001, Volume: 39, Issue:10 Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo	2001
Minoxidil in severe hypertension. Acta medica Scandinavica, 1978, Volume: 203, Issue:1-2 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Cardiac Output; Cardiomegaly; Clinical Trials as Top	1978
Acute and long-term salt depletion and beta-blockade: plasma renin activity response and its relation to blood pressure reduction in long-term treatment. Acta medica Scandinavica, 1978, Volume: 203, Issue:5 Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Diet, Sodium-Restricted; Diuretics; Female; Furo	1978
Minoxidil in resistant hypertension. Lancet (London, England), 1977, Sep-10, Volume: 2, Issue:8037 Topics: Blood Pressure; Drug Combinations; Female; Follow-Up Studies; Furosemide; Humans; Hypertension; Male	1977
[Treatment of essential hypertension with propranolol (author's transl)]. Deutsche medizinische Wochenschrift (1946), 1976, Oct-08, Volume: 101, Issue:41 Topics: Adult; Age Factors; Aldosterone; Blood Pressure; Clinical Trials as Topic; Creatinine; Cyclic AMP; F	1976
Reduction of plasma renin activity by inhibition of the fatty acid cyclooxygenase in human subjects: independence of sodium retention. Circulation research, 1979, Volume: 44, Issue:6 Topics: Adult; Aged; Aldosterone; Blood Pressure; Body Weight; Clinical Trials as Topic; Creatinine; Cycloox	1979
Sodium intake and furosemide administration in hypertensive patients with renal insufficiency. The American journal of cardiology, 1977, May-26, Volume: 39, Issue:6 Topics: Adult; Blood Pressure; Body Weight; Clinical Trials as Topic; Diet; Diet, Sodium-Restricted; Drug In	1977
Diuretic therapies in low renin and normal renin essential hypertension. Clinical pharmacology and therapeutics, 1977, Volume: 22, Issue:1 Topics: Adult; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Drug Combinations	1977
Intravenous diazoxide therapy in hypertensive crisis. The American journal of cardiology, 1977, Volume: 40, Issue:3 Topics: Adult; Aged; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinin	1977
Response of blood pressure and the renin-angiotensin-aldosterone axis to hypotensive therapy: comparison of propranolol with spironolactone. The New Zealand medical journal, 1977, Sep-14, Volume: 86, Issue:595 Topics: Adult; Aldosterone; Angiotensin II; Blood Pressure; Clinical Trials as Topic; Female; Furosemide; Hu	1977
[Therapy of severe hypertension with minoxidil, beta blockers and diuretics--long term results]. Verhandlungen der Deutschen Gesellschaft fur Kreislaufforschung, 1977, Volume: 43 Topics: Blood Pressure; Cardiac Output; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination	1977
Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. JAMA, 1978, Oct-20, Volume: 240, Issue:17 Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Furosemide; Humans; Hydrochlorothiazide; Hype	1978
Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension. European journal of clinical pharmacology, 1978, Dec-01, Volume: 14, Issue:4 Topics: Adult; Clinical Trials as Topic; Female; Furosemide; Humans; Hypertension; Male; Middle Aged; Natriu	1978
Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients. Archives of internal medicine, 1979, Volume: 139, Issue:9 Topics: Adult; Aged; Black or African American; Clinical Trials as Topic; Female; Furosemide; Humans; Hydroc	1979
Renin levels and spironolactone treatment in general practice: similar blood pressure lowering effect of spironolactone in low and normal renin patients. European journal of clinical investigation, 1977, Volume: 7, Issue:5 Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Furosemide; Humans; Hype	1977
Role of renin classification for diuretic treatment of black hypertensive patients. Archives of internal medicine, 1979, Volume: 139, Issue:12 Topics: Adult; Aged; Black or African American; Blood Pressure; Female; Furosemide; Humans; Hydrochlorothiaz	1979
[Influence of furosemide on beta-methyl-digoxin excretion in the urine (author's transl)]. Deutsche medizinische Wochenschrift (1946), 1978, Apr-14, Volume: 103, Issue:15 Topics: Adult; Aged; Digoxin; Drug Interactions; Female; Furosemide; Humans; Hypertension; Male; Middle Aged	1978
Plasma potassium in hypertensive Africans on frusemide. The Journal of international medical research, 1978, Volume: 6, Issue:3 Topics: Adult; Aged; Drug Therapy, Combination; Female; Furosemide; Humans; Hypertension; Hypokalemia; Male;	1978
Treatment of benign essential hypertension: comparison of furosemide and hydrochlorothiazide. European journal of clinical pharmacology, 1975, Aug-14, Volume: 8, Issue:6 Topics: Adult; Bicarbonates; Blood Pressure; Body Weight; Clinical Trials as Topic; Diuresis; Dose-Response	1975
Beta-adrenergic receptor blocking drugs, hypertension and plasma renin. British journal of clinical pharmacology, 1975, Volume: 2, Issue:2 Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Furosemide; Humans; Hypertension; Male; Middl	1975
Renin unresponsiveness and the effects of oxprenolol, methyldopa and spironolactone in pateints with essential hypertension. Australian and New Zealand journal of medicine, 1976, Volume: 6, Issue:3 Suppl Topics: Adult; Aged; Clinical Trials as Topic; Female; Furosemide; Humans; Hypertension; Male; Methyldopa; M	1976
Clinical and hemodynamic effects of high doses of slow release furosemide in arterial hypertension. A double-blind cross-over study with cyclopenthiazide. Acta medica Scandinavica. Supplementum, 1976, Volume: 602 Topics: Clinical Trials as Topic; Cyclopenthiazide; Delayed-Action Preparations; Diuretics; Dose-Response Re	1976
Effect of oxprenolol on catecholamines and plasma renin activity: acute response to frusemide in hypertensive patients. Clinical science and molecular medicine. Supplement, 1975, Volume: 2 Topics: Adult; Blood Pressure; Clinical Trials as Topic; Drug Interactions; Epinephrine; Furosemide; Heart R	1975
A randomized double-blind study of furosemide-reserpine in essential hypertension. Current therapeutic research, clinical and experimental, 1975, Volume: 18, Issue:3 Topics: Adult; Aged; Blood Pressure; Chlorides; Clinical Trials as Topic; Drug Therapy, Combination; Furosem	1975
Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension a two-year comparison of efficacy and safety. Angiology, 1977, Volume: 28, Issue:2 Topics: Double-Blind Method; Female; Furosemide; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Mal	1977
A double-blind study in hypertensive patients of an original new compound, indapamide. Current medical research and opinion, 1975, Volume: 3, Issue:1 Topics: Adult; Antihypertensive Agents; Benzamides; Blood Pressure Determination; Blood Proteins; Blood Urea	1975
Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension. Circulation research, 1975, Volume: 36, Issue:6 Suppl 1 Topics: Adult; Aged; Blood Pressure; Body Weight; Bromine; Chlorthalidone; Clinical Trials as Topic; Diet, S	1975
Aldosterone and renin in essential hypertension. Canadian Medical Association journal, 1975, Sep-06, Volume: 113, Issue:5 Topics: 18-Hydroxydesoxycorticosterone; Adult; Age Factors; Aldosterone; Angiotensin II; Clinical Trials as	1975
Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins, 1975, Volume: 10, Issue:4 Topics: Aldosterone; Blood Pressure; Clinical Trials as Topic; Drug Interactions; Furosemide; Humans; Hypert	1975
The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension. Clinical physiology and biochemistry, 1992, Volume: 9, Issue:3 Topics: Adolescent; Adult; Aged; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Drug The	1992
[Effects of furosemide, propranolol and nifedipine on urinary excretion of Tamm-Horsfall protein in patients with arterial hypertension]. Polskie Archiwum Medycyny Wewnetrznej, 1992, Volume: 88, Issue:4 Topics: Adult; Circadian Rhythm; Female; Furosemide; Humans; Hypertension; Male; Middle Aged; Mucoproteins;	1992
Single administration of captopril and combined use with beta-blocker and/or thiazide diuretic in the treatment of essential hypertension. Angiology, 1991, Volume: 42, Issue:11 Topics: Acebutolol; Adrenergic beta-Antagonists; Aldosterone; Benzothiadiazines; Blood Pressure; Captopril;	1991
Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice. Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 2 Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Cell Count; Br	1991
Maintenance of blood pressure control in elderly hypertensives on ketoprofen. Scandinavian journal of rheumatology. Supplement, 1991, Volume: 91 Topics: Acebutolol; Aged; Aged, 80 and over; Aging; Atenolol; Blood Pressure; Double-Blind Method; Drug Ther	1991
Cardiac changes from beta-blocker, diuretic and minoxidil combination in hypertension. Cardiology, 1991, Volume: 78, Issue:1 Topics: Betaxolol; Cardiomegaly; Drug Therapy, Combination; Edema; Furosemide; Humans; Hypertension; Male; M	1991
Chronotherapeutic study of furosemide in hypertensive subjects: a preliminary report. International journal of clinical pharmacology research, 1991, Volume: 11, Issue:2 Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Drug Administration Schedule; Electrolytes;	1991
Oral labetalol in hypertensive urgencies. The American journal of emergency medicine, 1991, Volume: 9, Issue:2 Topics: Administration, Oral; Adult; Blood Pressure; Clinical Protocols; Emergencies; Emergency Service, Hos	1991
[Efficacy of Triatec in monotherapy and in combination with Lasilix in a French multicenter study]. La Revue du praticien, 1990, Jun-21, Volume: 40, Issue:18 Suppl Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bridged Bicyclo Comp	1990
[Tolerance to Triatec in monotherapy and in combination with Lasilix in a French multicenter study]. La Revue du praticien, 1990, Jun-21, Volume: 40, Issue:18 Suppl Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bridged Bicyclo Comp	1990
Influence of captopril on urinary excretion of furosemide in hypertensive subjects. Journal of clinical pharmacology, 1990, Volume: 30, Issue:6 Topics: Adult; Aged; Angiotensin II; Captopril; Drug Therapy, Combination; Female; Furosemide; Humans; Hyper	1990
Influence of converting enzyme inhibition on glomerular filtration rate and proteinuria. Kidney international, 1990, Volume: 38, Issue:4 Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Female; Furos	1990
Effect of furosemide on angiotensin II-mediated prostaglandin I2 production in hypertensive subjects. European journal of clinical pharmacology, 1990, Volume: 39, Issue:2 Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Angiotensin II; Captopril; Dinoprostone; Double-Blind Met	1990
Treatment of severe hypertension with atenolol and betaxolol with once-daily regimens. Hemodynamic aspects. Chest, 1989, Volume: 96, Issue:3 Topics: Adrenergic beta-Antagonists; Atenolol; Betaxolol; Double-Blind Method; Drug Administration Schedule;	1989
Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney international, 1989, Volume: 36, Issue:4 Topics: Adult; Aged; Aldosterone; Body Weight; Chlorothiazide; Furosemide; Humans; Hypertension; Male; Middl	1989
Effects of atenolol and enalapril on blood pressure, plasma renin activity and urinary prostanoids. Clinical and investigative medicine. Medecine clinique et experimentale, 1988, Volume: 11, Issue:3 Topics: Adult; Aged; Atenolol; Blood Pressure; Creatinine; Enalapril; Female; Furosemide; Heart Rate; Humans	1988
Effect of intravenous enalaprilat in moderate and severe systemic hypertension. The American journal of cardiology, 1988, Nov-15, Volume: 62, Issue:16 Topics: Antihypertensive Agents; Double-Blind Method; Enalapril; Enalaprilat; Female; Furosemide; Humans; Hy	1988
Comparison of hydrochlorothiazide and slow release furosemide as adjuvant therapy to beta-blockers in the treatment of moderate hypertension. Acta medica Scandinavica, 1987, Volume: 222, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Dou	1987
Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. The American journal of medicine, 1988, Mar-11, Volume: 84, Issue:3A Topics: Adult; Angiotensin II; Blood Pressure; Captopril; Coronary Circulation; Exercise; Furosemide; Heart	1988
[Evaluation of the need for potassium supplementation in patients subjected to furosemide therapy]. Arquivos brasileiros de cardiologia, 1988, Volume: 51, Issue:2 Topics: Adult; Aged; Clinical Trials as Topic; Female; Furosemide; Heart Failure; Humans; Hypertension; Male	1988
Life quality in patients under hypotensive treatment. International journal of clinical pharmacology research, 1987, Volume: 7, Issue:1 Topics: Antihypertensive Agents; Blood Pressure; Captopril; Female; Furosemide; Heart Rate; Humans; Hyperten	1987
[Short-term antihypertensive effect of the combination of furosemide and amiloride]. Revista medica de Chile, 1987, Volume: 115, Issue:7 Topics: Amiloride; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Furosemide;	1987
Atenolol improves blood pressure control in patients taking captopril and frusemide. Journal of human hypertension, 1987, Volume: 1, Issue:2 Topics: Adult; Aged; Atenolol; Blood Pressure; Captopril; Clinical Trials as Topic; Double-Blind Method; Dru	1987
Atenolol or propranolol in hypertensive patients poorly controlled on captopril and frusemide. Journal of human hypertension, 1987, Volume: 1, Issue:2 Topics: Aged; Aldosterone; Atenolol; Blood Pressure; Captopril; Clinical Trials as Topic; Creatinine; Double	1987
An open study to compare the efficacy and tolerability of two diuretic combinations, frusemide plus amiloride and hydrochlorothiazide plus amiloride, in patients with mild to moderate essential hypertension. Current medical research and opinion, 1988, Volume: 10, Issue:10 Topics: Adult; Aged; Amiloride; Drug Combinations; Electrocardiography; Female; Furosemide; Heart Rate; Huma	1988
Effects of a low-sodium diet on antihypertensive and natriuretic responses to acute administration of nifedipine. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1987, Volume: 5, Issue:4 Topics: Adult; Aged; Blood Pressure; Combined Modality Therapy; Diet, Sodium-Restricted; Double-Blind Method	1987
Severe hypertension with cerebral symptoms treated with furosemide, fractionated diazoxide or dihydralazine. Danish Multicenter Study. Acta medica Scandinavica, 1986, Volume: 220, Issue:1 Topics: Adult; Aged; Antihypertensive Agents; Brain Diseases; Clinical Trials as Topic; Diazoxide; Dihydrala	1986
Reversibility of cerebral symptoms in severe hypertension in relation to acute antihypertensive therapy. Danish Multicenter Study. Acta medica Scandinavica, 1986, Volume: 220, Issue:1 Topics: Aged; Antihypertensive Agents; Brain Diseases; Clinical Trials as Topic; Diazoxide; Dihydralazine; D	1986
Torasemide, a new potent diuretic. Double-blind comparison with furosemide. European journal of clinical pharmacology, 1986, Volume: 31 Suppl Topics: Aged; Aged, 80 and over; Body Weight; Clinical Trials as Topic; Creatinine; Diuretics; Double-Blind	1986
[Effective blood pressure reduction and few side-effects in treatment with captopril and diuretics]. Lakartidningen, 1985, Jun-26, Volume: 82, Issue:26-27 Topics: Adult; Aged; Bendroflumethiazide; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Fe	1985
[Immediate and long-term antihypertensive effects of nifedipine in mild and moderate hypertension]. Arquivos brasileiros de cardiologia, 1985, Volume: 44, Issue:5 Topics: Adult; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Furosemide; Hear	1985
Effect of diuretic therapy on glucose tolerance in hypertensive patients. Lancet (London, England), 1971, May-15, Volume: 1, Issue:7707 Topics: Age Factors; Blood Glucose; Body Weight; Diabetes Mellitus; Diuretics; Ethacrynic Acid; Fasting; Fat	1971
[Therapeutic evaluation of uncomplicated hypertensive crises in emergencies]. Arquivos brasileiros de cardiologia, 1972, Volume: 25, Issue:4 Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Emergencies; Evaluation Studies as T	1972
Furosemide (Lasix). The Medical letter on drugs and therapeutics, 1972, Aug-18, Volume: 14, Issue:17 Topics: Abnormalities, Drug-Induced; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic	1972
Low-renin hypertension. Restoration of normotension and renin responsiveness. Archives of internal medicine, 1974, Volume: 133, Issue:2 Topics: Administration, Oral; Clinical Trials as Topic; Diet; Drug Therapy, Combination; Furosemide; Humans;	1974
Treatment of hypertension with large doses of the beta-adrenergic blocking drug oxprenolol, alone, and in combination with the vasodilator dihydralazine. Clinical science and molecular medicine. Supplement, 1973, Volume: 45 Suppl 1 Topics: Chlorothiazide; Clinical Trials as Topic; Drug Synergism; Furosemide; Heart Rate; Hydralazine; Hyper	1973
Clinical trial of a new diuretic--metindamide. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1974, Mar-16, Volume: 48, Issue:13 Topics: Adult; Aged; Benzamides; Blood Pressure; Chlorides; Clinical Trials as Topic; Depression, Chemical;	1974
Total body potassium in long-term Lasix therapy. Scottish medical journal, 1974, Volume: 19 Suppl 1 Topics: Aldosterone; Clinical Trials as Topic; Diuresis; Furosemide; Humans; Hydrochlorothiazide; Hypertensi	1974
Methyldopa combined with prindolol in the treatment of severe hypertension. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1974, Aug-10, Volume: 48, Issue:38 Topics: Blood Pressure; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Female; Furosem	1974
[Combined antihypertensive therapy using short and delayed-action saluretics. Studies on patients with essential hypertension]. Die Medizinische Welt, 1974, Jan-11, Volume: 25, Issue:2 Topics: Aged; Diuretics; Drug Evaluation; Furosemide; Humans; Hypertension; Middle Aged; Nicotinic Acids; Re	1974
[Clinical evaluation of terbolan]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 1968, Jun-01, Volume: 21, Issue:11 Topics: Adult; Aged; Clinical Trials as Topic; Female; Furosemide; Humans; Hypertension; Male; Middle Aged;	1968
[Biometric assay of the saluretic synergism of clopamide and furosemide]. Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology, 1969, Volume: 2, Issue:3 Topics: Adult; Aged; Amides; Aortic Valve Insufficiency; Biometry; Clinical Trials as Topic; Clopamide; Diur	1969
The significance of plasma renin determinations for differential diagnosis of hypertensiony. Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology, 1970, Volume: 4, Issue:1 Topics: Chronic Disease; Clinical Trials as Topic; Diagnosis, Differential; Diazoxide; Diet, Sodium-Restrict	1970
Furosemide in essential hypertension. A statistical analysis of three double-blind studies. Archives of internal medicine, 1971, Volume: 127, Issue:5 Topics: Adult; Aged; Aspartate Aminotransferases; Blood Cell Count; Blood Glucose; Blood Pressure; Blood Ure	1971
A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients. The Quarterly journal of medicine, 1971, Volume: 40, Issue:160 Topics: Adult; Aged; Blood Pressure; Blood Proteins; Carbon Dioxide; Clinical Trials as Topic; Female; Furos	1971
A comparison of the antihypertensive effects of furosemide and chlorothiazide. Current therapeutic research, clinical and experimental, 1970, Volume: 12, Issue:6 Topics: Adult; Blood Pressure; Chlorothiazide; Clinical Trials as Topic; Diuresis; Female; Furosemide; Human	1970
[Design and evaluation of a clinical study comparing combinations of antihypertensive agents]. Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology, 1971, Volume: 4, Issue:3 Topics: Analysis of Variance; Antihypertensive Agents; Biometry; Blood Pressure; Clinical Trials as Topic; C	1971
[Controlled clinical study of the blood pressure lowering effect of a rauwolfia-saluretic combination, with and without addition of an adrenolytic agent]. Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete, 1971, Volume: 52, Issue:5 Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Clopamide; Diuretics; Ergoloid Me	1971
Clinical trial of mefruside, a new diuretic. British medical journal, 1971, Dec-25, Volume: 4, Issue:5790 Topics: Adult; Aged; Chlorides; Diuresis; Diuretics; Edema; Female; Furosemide; Humans; Hypertension; Male;	1971
[Clinical evaluation of a new diuretic]. Gazzetta medica italiana, 1965, Volume: 124, Issue:12 Topics: Clinical Trials as Topic; Diuretics; Furosemide; Heart Failure; Humans; Hypertension; Liver Cirrhosi	1965
[Clinical-pharmacologic studies and therapy with anti-hypertensive furosemide-reserpine preparations]. Medizinische Klinik, 1971, Aug-13, Volume: 66, Issue:23 Topics: Blood Glucose; Blood Pressure Determination; Blood Urea Nitrogen; Creatinine; Diuresis; Drug Synergi	1971
[Hemodynamics and excretory function of the kidney during furosemide and diazoxide administration. A contribution to the regulation of renin activity]. Die Medizinische Welt, 1971, Apr-17, Volume: 16 Topics: Diazoxide; Electrolytes; Furosemide; Hemodynamics; Humans; Hypertension; Kidney; Renin	1971

furosemide and Blood Pressure, High

Research Excerpts

Research

Studies (994)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Change in Diastolic Blood Pressure

Change in Extracellular Water

Change in Extracellular Water / Total Body Water Ratio

Change in Mean Arterial Pressure

Change in Systolic Blood Pressure

Change in the Fractional Excretion of Sodium

Change in Total Body Water

Mean Arterial Blood Pressure (MAP)

Breastfeeding Status

Change of Dose for Antihypertensive Therapy

Hospital Length of Stay

Hospital Readmission

Change of Gestational Hypertensive Disorder Symptoms (Diastolic BP)

Change of Gestational Hypertensive Disorder Symptoms (Mean Arterial Pressure)

Change of Gestational Hypertensive Disorder Symptoms (Systolic BP)

Aortic Augmentation Index

Brachial Artery Flow-mediated Dilation (FMD)

Carotid-femoral Pulse Wave Velocity

Diurnal Variation in Ambulatory Blood Pressure

Mean 24-hour Systolic Blood Pressure

Six Minute Walk Test Distance

Urinary 8-isoprostanes

Ventricular Diastolic Function

Geometric Mean Ratio of Area Under Curve

Geometric Mean Ratio of Maximum Concentration

Pharmacokinetics Parameter

Pharmacokinetics Parameter

Reviews

Trials

Other Studies

Authors	Studies
Stokker, GE	1
Smith, RL	1
Cragoe, EJ	1
Ludden, CT	1
Russo, HF	1
Sweet, CS	1
Watson, LS	1
Zhu, Y	1
de Jesus, RK	1
Tang, H	1
Walsh, SP	1
Jiang, J	1
Gu, X	1
Teumelsan, N	1
Shahripour, A	1
Pio, B	1
Ding, FX	1
Ha, S	1
Priest, BT	1
Swensen, AM	1
Alonso-Galicia, M	1
Felix, JP	1
Brochu, RM	1
Bailey, T	1
Thomas-Fowlkes, B	1
Zhou, X	1
Pai, LY	1
Hampton, C	1
Hernandez, M	1
Owens, K	1
Ehrhart, J	1
Roy, S	1
Kaczorowski, GJ	1
Yang, L	1
Parmee, ER	1
Sullivan, K	1
Garcia, ML	1
Pasternak, A	1
Cechinel-Zanchett, CC	1
Bolda Mariano, LN	1